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The trillions of bacteria that inhabit the gastrointestinal tract, known collectively as the 
gut microbiome, are essential for both health and the normal functioning of the intestine.  
A growing literature now suggests that disruptive changes to this community are 
strongly associated with the development of colorectal cancer.  However, it is unclear 
whether these disruptive changes directly contribute to disease or if they are just a 
consequence of colorectal cancer (CRC).  Furthermore, the gut microbiome has not 
been explored as a potential non-invasive screen for CRC.  Our hypothesis is that 
abnormalities in the gut microbiome can be utilized as a biomarker for detection of CRC 
at its earliest stages.  Additionally, we postulate that these changes potentiate tumor 
development in the colon.  To test these hypotheses, we first characterized the gut 
microbiome associated with human patients from three clinical groups representing 
three essential stages in CRC development: healthy, adenoma, and carcinoma.  We 
demonstrated that a specific set of bacterial populations are associated with adenomas 
and carcinomas.  The abundance of these bacterial populations was used to improve 
our ability to differentiate between healthy and diseased subjects and presents a viable 
screening tool for the earliest stages of CRC development.  Next, we demonstrated 
using a mouse model of inflammation-driven colon cancer that there are dramatic, 
continual alterations in the gut microbiome during the development of tumors.  By 
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colonizing germ-free mice with the gut microbiome from tumor-bearing mice, we 
determined that these changes are directly responsible for increased tumor 
development.  Using an antibiotic cocktail, we were able to demonstrate that 
manipulation of this microbial community can dramatically reduce tumor burden in mice.  
By varying the composition of this antibiotic cocktail we generated a broad spectrum of 
microbial communities with varying carcinogenic capacities. This method of 
manipulating the gut microbiome allowed us to identify potentially protective and 
carcinogenic bacterial populations for further mechanistic studies.  Our results 
demonstrate that changes to the gut microbiome can serve as an effective non-invasive 
screen for the early detection of colorectal cancer and that interventions that target 










Prevalence of Colorectal Cancer 
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy 
worldwide, accounting for over a half million deaths annually [Siegel et al., 2007; Parkin 
et al., 2005]. The lifetime risk of developing CRC is about 1 in 20 for both men and 
women, however incidence and mortality rates are about 40% higher in men [American 
Cancer Society, 2011; Fearon et al., 2011].  Risk can be become substantially higher 
depending on various genetic and environmental factors, which I will discuss in the 
following sections.  It is estimated that the annual economic burden for CRC care in the 
United States (US) is approximately $14 billion.  This number is expected to continue to 
rise as average life expectancy increases and the pool of at risk population grows 
[Mariotto et al., 2011].  In this chapter, I will summarize what is known about the 
development and progression of CRC, and I will discuss current recommended 
screening procedures and their limitations.  I will also introduce the potential role for a 
largely understudied variable in CRC, the gut microbiome, and discuss its potential as a 






Figure 1.1.  The adenoma-carcinoma progression.  Modified from Fearon et al., 





















A.  Sporadic CRC 
B.  FAP 
C.  HNPCC 
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The Adenoma-Carcinoma Sequence 
 CRC development is a multistep process by which healthy epithelium develops 
into pre-cancerous polyps, which in turn progress into malignant carcinomas overtime 
(Figure 1.1).  Over 95% of CRCs are adenocarcinomas that developed from glandular 
tissue in the colon [Stewart et al., 2006].  The large majority of these cancers arise from 
adenomatous polyps, which are thought to be the main precursor legion in CRC.  
Adenomas are highly prevalent legions, with over one-third of people eventually 
developing an adenoma in their lifetime; however, only 10% of adenomas will progress 
to CRC in a 10-year period [Levine et al., 2006].  An early and potentially rate limiting 
step to the development of an adenomas is thought to be an inactivating mutation to the 
adenomatous polyposis coli (APC) gene [Fearon et al., 2011].  This APC gene is an 
important tumor suppressor gene that regulates epithelial cell proliferation through the 
Wnt pathway [Goss et al., 2000].  It is estimated that 80% of sporadic adenomas have a 
somatic mutation in the APC gene and this mutation can be seen at the earliest stages 
of adenoma growth.  Although it is thought to be a gatekeeper mutation in tumor 
development, this mutation is not sufficient for the progression to CRC; accumulation of 
additional mutations is necessary.  Currently, our understanding of the genetic and 
environmental factors that promote mutations in tumor suppressor genes at each step in 
this progression is limited.  Further work is needed to clarify the role of genetic, 
immunological, and environmental factors in this process. 
 
Colorectal Cancer Screening and Surveillance 
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The survival rate for CRC is over 90% if diagnosis occurs while the cancer is still 
localized; however, survival drops dramatically when a cancer grows through the 
intestinal wall and becomes metastatic [Hayat et al., 2007; Ries et al., 2007].  This 
highlights the importance of detecting and diagnosing CRC at its earliest stages.  With 
advancements in screening and surveillance of CRC, incidence rates have been in 
steady decline since the 1980s [Epsey et al., 2007].  Direct inspection of the mucosa by 
colonoscopy is currently one of the most accurate and preferred methods for prevention 
of CRC in the US.  Colonoscopies have a number of advantages, including the ability to 
examine the entire colon, remove polyps, and diagnose CRC with high sensitivity 
[American Cancer Society, 2011].  It is recommended that people with a history of CRC 
or those over the age of 50 receive colonoscopies every 10 years [Sonnenberg et al., 
2000; Levin et al., 2008].  These examinations have led to a dramatic decrease in CRC 
mortality and it has been estimated that colonoscopy screening has the potential to 
completely prevent 65% of CRC cases [Brenner et al., 2007].  However, colonoscopy 
has a substantial risk of complications, requires significant preparation, and is invasive 
for the patient.  Surveys have estimated that more than 30% of adults do not receive 
age and risk appropriate screenings, and over 50% of adults prefer other screening 
methods [Benson et al., 2007; Leard et al., 1997; Ling et al., 2001].  Furthermore, the 
healthcare costs of screening by colonoscopy are estimated in some studies to be over 
$2.7 billion in the US [Fisher et al., 2006].  Thus, there is a clear need for the 
development of non-invasive screening methods to prioritize individuals for further 




Non-invasive Screening of Colorectal Cancer 
One of the most commonly utilized non-invasive screens for CRC is the guaiac 
fecal occult blood test (gFOBT), which detects blood in an individual’s feces [Allison et 
al., 1996].  Occult blood in the stool can indicate the presence of advanced adenomas 
and carcinomas in the colon, although some non-related disorders or dietary factors 
may result in a false positive test.  Because of the potential for false positive tests, the 
sensitivity for gFOBT can be as low as 9-12%, rendering it a non-feasible option for 
screening.  However, with repeated testing, typically up to 3 fecal samples and 6 
repeated tests, the sensitivity can be significantly improved [Lieberman et al., 2001; 
Levin et al., 2008].  Despite these limitations, gFOBT has shown to reduce CRC 
mortality up to 30%.  CRC mortality rates could drop even further upon development of 
a more sensitive non-invasive screening method.  Clearly, there is a need for novel 
biomarkers of CRC that could be used for screening. 
 
Heredity and Family History in Colorectal Cancer 
About 20-30% of CRC cases are estimated to have a significant hereditary 
component [Taylor et al., 2010].  Individuals with a first degree relative who has had 
CRC are at least two times as likely to develop CRC; moreover that risk increases if that 
family member developed cancer at an early age [Butterworth et al., 2006].  Two well-
defined inherited syndromes that greatly increase the risk of CRC are familial 
adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC).  
Patients with FAP have a germline inactivating mutation in the APC gene, which results 
in the development of hundreds of colonic polyps at an early age and inevitably leads to 
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CRC [Galiatsatos, et al., 2006].  Individuals with HNPCC, also known as Lynch 
syndrome, do not develop polyps at an early age; however, polyps that do appear tend 
to become malignant at a higher rate and in a short period of time [Dove-Edwin et al., 
2006].  The majority of patients with FAP, and some with HNPCC, require prophylactic 
removal of the colon relatively early in life to prevent the inevitable onset of CRC.  
Together, FAP and HNPCC only make up about 5% of all CRC cases [Fearon et al., 
2011], but these syndromes have allowed researchers to uncover many of the 
mechanisms of tumor development and progress in the colon. 
 
Risk Factors for Colorectal Cancer 
 Approximately 70% of CRC cases develop sporadically and have no known 
causative agents.  Epidemiological studies have identified several potential risk factors 
for CRC, including age and chronic inflammation of the gastrointestinal tract.  CRC risk 
rises substantially with age, and there is a sharp increase in incidence at the age of 50.  
In fact, over 90% of CRC cases occur in people over 50 [Benson et al., 2007].  This is a 
clear problem because as the average life expectancy continues to rise, the pool of 
individuals at an increased risk of CRC also grows.  Additionally, patients with chronic 
inflammatory diseases, such as inflammatory bowel disease, are at an increased risk.  
In the case of ulcerative colitis, the risk for CRC increases 1% per year after the first 
decade [Chambers et al., 2005; Ullman et al., 2011; Eaden et al., 2000].  The potential 
mechanisms by which this chronic inflammation may drive tumorigenesis will be 





Risk Factors for Colorectal Cancer 
Age 
• 50 years and older 
Previous cases of colorectal cancer 
Family History colorectal cancer 
Inheritable Syndromes 
• Familial adenomatous polyposis 
• Hereditary nonpolyposis colorectal cancer 
Environmental factors 
• Diet high in red meat 
• Diet high in fat 
• Diet low in fiber 
• Obesity (BMI) 
• Physical inactivity 
• Smoking 
• Alcohol 
Chronic inflammation of Gastrointestinal tract 
• Inflammatory bowel disease 
§ Crohn’s disease 
§ Ulcerative colitis 
 
Table 1.1 Risk factors for colorectal cancer.  Summary of the known risk factors for 





In addition to age and inflammation, several behavioral and environmental risk 
factors have been identified for CRC including obesity, physical inactivity, alcohol 
consumption, and diet (Table 1.1).  One recent study suggested that individuals with a 
lifetime average of 2-4 alcoholic drinks per day have a 20% higher risk of CRC.  Diet, 
which is closely linked to obesity, has been associated with CRC incidence in a number 
of studies.  It has been shown that diets high in red and processed meat, or high in fat 
are linked to an increased risk of CRC [Butler et al., 2003].  It has been known for 
sometime now that high fat diets play a role in CRC.  Rodents fed a high fat diet 
develop significantly more tumors in experimental mouse models of CRC [Wasan et al., 
1997].  High fiber diets, on the other hand, have been suggested to decrease risk [Aune 
et al., 2011], although this effect is still debated.  Support for a significant role of dietary 
factors in the etiology of CRC can also be seen in epidemiology studies.  US-born 
Japanese men experience a rate of CRC that is double than the observed rate in native 
Japanese men [Flood et al., 2000].  This phenomenon is also seen in African 
Americans, who have a dramatic increase in CRC incidence compared to native 
Africans [O’Keefe et al., 2007].  The factor that is contributing to the disparity in CRC 
incidence is likely diet, which varies greatly in each of these cases.  The mechanisms by 
which these environmental factors, such as diet, affect the development of CRC has 
largely remained unknown.  However, a recent appreciation for the complex community 
of microorganisms that inhabit the gastrointestinal tract has began to shed light on this 
phenomenon. 
 
The Gut Microbiome 
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The human gastrointestinal tract is home to trillions of microorganisms, which 
outnumber human cells by 10-fold [Backhed et al., 2005].  Taken together, these 
microbes harbor over 100 times as many genes as their human host [Gill et al., 2006].  
This has lead researchers to suggest that the gut microbiome is essentially a microbial 
organ within the host and moreover has lead some to consider the host and its 
microbes as a super-organism.  The gut microbiome is an incredibly diverse community 
of microorganisms with a complex ecology that we are just beginning to understand.  
This community consists of bacteria, viruses, phage, and eukaryotes, which all interact 
with each other and the host [Guarner et al., 2003; Backhed et al., 2005].  In my thesis I 
will only be focusing on the bacterial component of the gut microbiome, which makes up 
the majority of the microbes present; however, consideration for the other members of 
the community is essential for a complete understanding of the underlying mechanisms 
of tumorigenesis.  Symbiotic members of gut microbiome are often termed commensal, 
meaning they benefit from the relationship without affecting the host, but in reality this 
relationship is more mutualistic.  This is supported by a wealth of literature that has 
determined that an intact microbial community is essential for development and health 
of the host [Alonso et al., 2013; Backhed et al., 2005].  The vast diversity in genetic 
potential harbored by the gut microbiome provides for a large arsenal of metabolic 
enzymes that aid the host in digestion, energy harvest, and vitamin synthesis.  These 
microorganisms supply most of the vitamin K and water-soluble B vitamins needed by 
the host [Guzman et al., 2013].  Beyond digestion, the gut microbiome has a much more 
direct affect on the host.  Extensive research has shown that the gut microbiome is 
needed for the proper development and maturation of the immune system.  Germ-free 
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mice, which are completely devoid of any microbes, have a dramatically 
underdeveloped immune system and mucosal barrier [Mazmanian et al., 2005; 
Tlaskalova-Hogenova et al., 2011].  Another important feature of the gut microbiome is 
its ability to confer colonization resistance, which is a natural barrier that is capable of 
preventing the establishment of pathogenic bacteria [Vollaard et al., 1994].  
Perturbations to the community can leave the host susceptible to colonization by enteric 
pathogens like Clostridium difficile, highlighting the importance of a healthy microbial 
community [Reeves et al., 2011; Theriot et al., 2014].  
 
Dysbiosis and Colorectal Cancer 
 Although the gut microbiome is important for maintaining health in the host, it has 
also been associated with various diseases, including inflammatory bowel disease and 
obesity.  In each of these diseases a phenomenon, termed dysbiosis, is observed in the 
gut microbiome.  Dysbiosis is defined as an abnormal community structure or 
composition of the gut microbiome.  Several recent studies have shown that this 
phenomenon can be observed in the feces of individuals with CRC relative to healthy 
controls [Chen et al., 2013; Chen et al., 2012; Kostic et al., 2012; Geng et al., 2013; 
Shen et al., 2013; Sobhani et al., 2011; Wang et al., 2012; Ahn et al., 2013].  
Interestingly, each of these groups obtained conflicting results regarding the 
composition and structure of the CRC-associated community.  CRC-associated 
dysbiosis is not limited to feces, as demonstrated by two groups who recently reported 
an enrichment of Fusobacterium nucleatum on the surface of colonic tumors relative to 
adjacent healthy tissue.  Furthermore, it was shown that sequences from 
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Fusobacterium spp. could be detected in the feces of patients with CRC [Ahn et al., 
2013; Kostic et al., 2013].  These data clearly show a link between the structure and 
composition of the gut microbiome, and CRC; however, it remains unclear whether 
abnormalities in the gut microbiome directly affect colon tumorigenesis or if they are 
simply an unrelated consequence.  Regardless, it is tempting to speculate on the 
potential of using these abnormal changes in the gut microbiome as a way to determine 
if a person has CRC or is at an increased risk.  
 
Diet, The Gut Microbiome, and CRC 
Beyond dysbiosis, there are several clear links between the gut microbiome and 
CRC.  The gut microbiome is directly associated with several important risk factors for 
CRC, including diet.  Diet has been shown to be an important mediator of microbial 
community structure and composition, and certain dietary components have an 
important role in the function of the gut microbiome [David et al., 2013].  A significant 
portion of the human diet consists of carbohydrates, such as starches, cellulose, 
hemicellulose, and pectins, which are non-digestible by the host.  When these non-
digestible carbohydrates reach the colon, resident microbes ferment them and produce 
short chain fatty acids (SCFAs).  SCFAs serve an important role in colonic health and 
provide important nutrients for colonocytes and other epithelial cells [Koropatkin et al., 
2012].  Evidence suggests that SCFAs, specifically butyrate, also affect various 
physiological functions that are directly associated with cancer, including cell 
proliferation, angiogenesis, and apoptosis [Ruemmele et al., 2003; Segain et al., 2000; 
Hague et al., 1995].  In cell culture, butyrate has been shown to reduce proliferation and 
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induce apoptosis of tumor cells.  Several studies have shown that diets high in fiber and 
carbohydrates can increase beneficial bacterial taxa that produce butyrate [Hague et al., 
1995; Ruemmele et al., 2003].  Furthermore, butyrate has been shown to be 
significantly decreases in the colon of subjects with CRC [Wang et al., 2012; Chen et 
al., 2013].  Conversely, it has been shown that diets high in fat and low in fiber shift the 
structure of the gut microbiome in a potentially detrimental way [Peters et al., 1992].  
These diets likely lead to a dramatic decrease in SCFA production and subsequently 
decrease epithelial health and mucin production [Willemsen et al., 2003; Hatayama et 
al., 2007].  It is also known that diets can contain various levels of toxic, carcinogenic, or 
mutagenic compounds.  Members of the gut microbiome have the potential to both 
activate and detoxify these compounds. The composition and functional potential of the 
community could largely affect the metabolism of these chemicals and the subsequent 
affect on the host [Rowland, 1988].  Taken together this evidence leads us to the 
hypothesis that manipulation of the gut microbiome with diet could help in prevention 
and treatment of cancer.   
 
Inflammation, the Gut Microbiome, and CRC 
Another important link between the gut microbiome and CRC is inflammation.  
We have known for sometime now that chronic inflammation is directly linked to many 
cancers.  In the gastrointestinal tract, the main driver of this inflammation is the resident 
microbes, their gene products, and the metabolites they produce.  Gut microbes are 
recognized by a repertoire of pattern recognition receptors (PRRs) that are specific for 
conserved microbial patterns, such as components of the bacterial cell wall or nucleic 
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acids.  Two important PRRs are Nod-like receptors (NLRs) and Toll-like receptors 
(TLRs), which initiate signaling cascades upon activation by microbial signals [Abreu et 
al., 2005].  These signal cascades activate various transcriptional regulators, including 
nuclear factor of kappa B (NFκB), which modulates inflammation, cell proliferation, and 
apoptosis [Rakoff-Nahoium et al., 2008].  The importance of PRRs and NFκB in CRC 
has been extensively studied in various mouse models of tumorigenesis.  Mice deficient 
in TLR4, which recognizes lipopolysaccharide (LPS), show a marked decrease in colon 
tumorigenesis [Fukata et al., 2007].  Furthermore, myeloid differentiation factor 88 
(MyD88) deficient mice, which is the main adaptor protein for signaling through the 
majority of TLRs, show a diminished development of colorectal cancer [Uronis et al., 
2009].  When NFκB is deactivated in IκB kinane (IKK) deficient mice, there is also a 
dramatic decrease in CRC [Greten et al., 2004].  Together these experiments clearly 
demonstrate that signaling through PRRs directly modulates tumorigenesis in the colon.  
The mechanisms by which NFκB-mediated inflammation can promote tumorigenesis 
include the production of pro-tumorigenic cytokines and chemokines like tumor necrosis 
factor alpha (TNF- α), interleukin 1 beta (IL-1β), IL-8, and IL-6 [Karin et al., 2005].  
These inflammatory cytokines are produced by lamina propria myeloid cells and 
stimulate growth and survival of malignant cells in the gastrointestinal tract [Grivennikov 
et al., 2009].  Chemokine production leads to the recruitment of immune cells, such as 
neutrophils, to the tumor microenvironment [Fridlender et al., 2012].  It is thought that 
infiltration by neutrophils can increase carcinogenesis and initiate accumulation of 
mutations through the production of reactive oxygen species (ROS).  In addition to the 
production of cytokines and the recruitment of immune cells, NFκB can also promote 
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tumorigenesis through its ability to suppress the apoptosis of pre-cancerous progenitor 
cells [Karin et al., 2005].  In summary, recognition of the gut microbiome by the host and 
subsequent inflammatory responses can directly promote tumorigenesis. However it 
remains largely unknown how the composition, structure, and function of the gut 
microbiome affect these mechanisms. 
 
Bacteria Associated with CRC 
The microbial influence on CRC is highlighted by several studies that have 
shown that mice raised in germ-free conditions develop significantly less tumors in 
various models of CRC [Dove et al., 1997; Uronis et al., 2009].  Recently, several 
specific members of the gut microbiome have become of particular interest in CRC 
(Table 1.2).  One of the most intriguing of these microbes is Fusobacterium nucleatum, 
which was described previously in this chapter as being enriched on the surface of 
tumors.  F. nucleatum is not a typical member of the gut microbiome; it is only seen in 
about 6% of healthy individuals (Unpublished data from Schloss laboratory).  However, 
it is a normal commensal of the mouth [Signat et al., 2011].  A recent study determined 
that when fed to mice, this pathogen promotes tumorigenesis by recruiting myeloid cells 
to the tumor and generating a proinflammatory microenvironment [Kostic et al., 2013].  It 
still remains to be determined whether the F. nucleatum in the colon is the same as that 
in the mouth.   
Several more common commensal bacteria have also been linked to CRC.  A 
recent study demonstrated that colonic inflammation in the IL-10-deficient mouse 
impacts the composition of the gut microbiome, leading to an enrichment of tumor 
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promoting Escherichia coli strains [Arthur et al., 2012].  These strains have a polyketide 
synthase (pks) genotoxic island that increases the rate by which tumors progress.  
Similarly, human commensals belonging to the genus Bacteroides, specifically 
enterotoxigenic B. fragilis (ETBF), have been associated with inflammation and CRC 
[Wu et al., 2009; Sears et al., 2008].  ETBF has been shown to strongly induce colonic 
tumors in mice through secretion of a metalloprotease toxin and certain strains are 
thought to contribute to CRC risk in humans.  Finally, it has been known that 
Streptococcus bovis has been linked to CRC since as early as the 1950’s [Galdy et al., 
2012].  Survey studies have reported a strong correlation between this bacterial species 
and CRC.  It is clear that several microbes have a direct affect in the development and 
progression of CRC; however, survey studies rarely show the same bacterial profile 
between subjects with CRC.  Furthermore, only a small percent of subjects have 
detectable levels of populations like E. coli and ETBF.  This strongly suggests that there 
may be multiple underlying mechanisms by which the microbiome is involved in CRC 




Bacteria Associated with Colorectal Cancer 
Bacteria Link to colorectal cancer 
Fusobacterium nucleatum 
Enriched on tumors and increases 
tumorigenesis in APC min mouse 
model. 
Bacteroides fragilis 
Enterotoxigenic B. fragilis has 
metalloprotease toxin linked to cancer.  
Increases tumorigenesis in APC min 
mouse. 
Escherichia coli 
Strans with polyketide synthase 
genotoxic island increase rate of tumors 
progression in Il-10 deficient mice.  
Streptococcus bovis Linked to colorectal cancer in survey-based studies of stool. 
Helicobacter hepaticus Increases tumorigenesis in APC min mice 
Helicobacterer pylori Causative agent of ulcers, which increase risk of colorectal cancer 
Citrobacter rodentium Increases tumorigenesis in mouse models of colorectal cancer 
 
Table 1.2. Bacteria associated with colorectal cancer.  Bacteria that have been 




Microbial Ecology in the Gut Microbiome 
The limitation of studies that have looked at the role of individual microbes in 
CRC is that they ignore the fact that the gut microbiome is a diverse and complex 
community of microorganisms.  This community has a complex ecology with a wide 
array of microbe-microbe interactions [Konopka et al., 2009].  Interactions that occur 
include complex signaling, competition for resources and space, metabolic interactions, 
and structural interactions (i.e. biofilms) [Konopka et al., 2009].  The importance of this 
ecology in relation to disease can be highlighted by the syntrophic interaction between 
Archaea in periodontal disease [Lepp et al., 2004].  In this system methanogenic 
Archaea acted as a hydrogen sink to allow for the proliferation of pathogenic bacteria to 
a level that would not be possible in the absence of this syntrophy.  In CRC, bacteria 
like Fusobacterium spp. or E. coli are likely heavily influenced by the bacterial 
community surrounding them.  Their pathogenicity may rely solely on interactions with 
other microbes, and thus studying them out of this context may be misleading.  In the 
subsequent chapters of my thesis, I will emphasize the importance of the entire 
community and the complex ecology when characterizing the role of the gut microbiome 
in CRC.  This is not to downplay the importance of understanding the mechanisms by 
which individual microbes affect CRC, but we need to understand how the community 
as a whole affects CRC before we begin to ask more mechanistic questions.  
 
Summary and Chapter Outline 
 Colorectal cancer (CRC) is one of the deadliest malignancies worldwide, 
affecting millions of people each year.  Significant risk factors for CRC, including diet 
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and chronic inflammation, are intimately linked with the gut microbiome.  Furthermore, 
the gut microbiome promotes various physiological functions that are closely associated 
with cancer, including cell proliferation, angiogenesis, and apoptosis.  Several recent 
survey-based studies have reported the people with CRC have a dysbiotic gut 
microbiome.  However, it is unclear how these changes develop over time and whether 
they directly affect tumorigenesis or if they are an unrelated consequence of CRC 
development.  Therefore the primary goal of this thesis research is to understand the 
role of the gut microbiome in CRC.  We hypothesize that the composition, structure, and 
functional capacity of the gut microbiome all directly affect tumor development in the 
colon.  Additionally, we believe that understanding how dysbiosis develops over time 
will allow us to develop novel methods for using the gut microbiome as a biomarker for 
CRC. 
In chapter II, we collected samples from human subjects that represented three 
clinical groups: healthy, adenoma, and carcinoma.  We investigated the potential of 
using the gut microbiome as a biomarker for CRC by identifying significantly enriched 
bacterial populations in each group.  We demonstrated that incorporation of microbial 
biomarkers into logit models, generated using common risk factors for CRC, and 
significantly improved our ability to predict the presence of both pre-cancerous 
adenomas and carcinomas.   
In chapter III, we characterized the gut microbiome in a mouse model of CRC 
and determined that mice develop dysbiosis that mirrors that seen in humans.  Using 
machine-learning algorithms, we were able to accurately predict the presence of tumors 
in the colon based solely on the structure of the gut microbiome.  Using germ-free mice 
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we demonstrated for the first time that tumor-associated changes in the gut microbiome 
increase tumorigenesis in the colon.  Additionally, manipulation of this community with 
antibiotics dramatically reduced tumor incidence in mice.   
To further explore the effect of community structure on tumorigenesis, we treated 
mice with a wide array of different antibiotic treatments.  In chapter IV, we identify 
several potentially carcinogenic and protective bacterial populations in the gut 
microbiome.  We also show that changes in community structure and diversity have a 
dramatic affect on tumor incidence in the colon.  Using antibiotics as an intervention, we 
demonstrate that modulation of the gut microbiome at the first signs of dysbiosis can 
reduce tumorigenesis.  This strongly suggests that targeting of the gut microbiome for 
therapeutic purposes may be an effective strategy for CRC prevention.  Chapter V 
includes a summary of the results, future areas of study, and conclusions including a 
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Recent studies have suggested that the gut microbiome may be an important 
factor in the development of colorectal cancer (CRC).  Abnormalities in the gut 
microbiome have been reported in patients with CRC; however, this microbial 
community has not been explored as a potential screen for early stage disease.  We 
characterized the gut microbiome in patients from three clinical groups representing the 
stages of CRC development: health, adenoma, and carcinoma.  Analysis of the gut 
microbiome from stool samples revealed both an enrichment and depletion of several 
bacterial populations associated with adenomas and carcinomas.  Combined with 
known clinical risk factors of CRC (e.g. BMI, age, race), data from the gut microbiome 
significantly improved the ability to differentiate between healthy, adenoma, and 
carcinoma clinical groups relative to risk factors alone.  Using Bayesian methods, we 
determined that using gut microbiome data as a screening tool improved the pre-test to 
post-test probability of adenoma over 50-fold.  For example, the pre-test probability in a 
65 year-old was 0.17% and, after using the microbiome data, this increased to 10.67% 
(1 in 9 chance of having an adenoma).  Taken together the results of our study 
demonstrate the feasibility of using the composition of the gut microbiome to detect the 
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presence of precancerous and cancerous lesions.  Furthermore, these results support 
the need for more cross sectional studies with diverse populations and linkage to other 




Worldwide, colorectal cancer (CRC) is the third most commonly diagnosed 
malignancy and accounts for over a half million deaths annually [Parkin et al., 2005].  
Development of CRC is a stepwise process by which localized precancerous 
adenomatous polyps (adenomas) develop in the colon and progress into invasive and 
metastatic cancerous tumors (carcinomas) overtime [Fearon, 2011; Jass, 2007].  
Development of carcinomas is largely preventable if adenomas are detected and 
removed [Levin et al., 2008], with a CRC survival rate exceeding 90% if the diagnosis 
occurs while the disease is still localized. However, there is a dramatic decline in 
survival following invasion and metastasis [SEER program, 2013].  Thus, early detection 
at the adenoma stage of this disease has been critical for successful treatment and 
survival. 
From 1975 to 2010, death rates from colorectal cancer have steadily decreased 
in the United States, with a 2.8% average annual decline [SEER program, 2013].  
Screening with high sensitivity fecal occult blood testing (FOBT), sigmoidoscopy, and 
colonoscopy has improved survival rates and is recommended for adults 50 to 75 years 
of age [Whitlock et al., 2008].  In particular, colonoscopies allow for full examination of 
the bowel with the opportunity for same-session colonic biopsies and removal of polyps.  
	  
 29	  
However, over 30% of adults in the US do not receive age and risk-appropriate 
screenings and surveys indicate that 50-60% of adults prefer non-invasive screening 
methods [Benson, 2007; Learn et al., 1997; Ling et al., 2001].  Lack of compliance with 
these recommendations may be due in part to the intrusiveness and uncomfortable 
nature of the colonoscopy procedure.  Furthermore, the healthcare costs of screening 
for CRC by colonoscopy are considerable, ranging from $800 to $3160 per procedure in 
2012 which was undergone by more than 48 million 50-75 year-old Americans [Joseph 
et al., 2012; Howden and Meyer, 2012].  Therefore, there is a need to develop cost-
effective non-invasive screening methods to prioritize individuals for further evaluation 
by colonoscopy.  One of the most commonly used non-invasive screening procedures is 
the guaiac fecal occult blood test (gFOBT), which detects blood in an individual’s feces 
[Allison et al., 1996].  Occult blood in stool can indicate the presence of advanced 
adenomas and carcinomas in the colon, but can also indicate a wide variety of other 
disorders and factors that may lead to false positive tests [Young et al., 2002]. Although 
the specificity of the method ranges from 87-98% [Allison et al., 1996], the sensitivity 
can be as low as 9-12% [Collings et al., 2005; Imperiale et al., 2004].  With repeated 
testing using multiple stool samples and regular screening intervals, sensitivity can be 
dramatically improved [Lieberman et al., 2001; Levin et al., 2008].  Despite these 
limitations, gFOBT has been shown to reduce mortality from CRC by 15 to 33%, 
highlighting the effectiveness of non-invasive screening measures [Hardcastle et al., 
1996; Kronborg et al., 1996; Mandel et al., 1999; Mandel et al., 2000].   
Approximately 70% of CRC cases develop spontaneously and are of unknown 
etiology [Fearon, 2011].  Factors associated with increased risk of CRC include diet, 
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alcohol, and chronic inflammation of the gastrointestinal tract [Chambers et al., 2005; 
Huxley et al., 2009; Larsson et al., 2005; Slattery, 2000].  Recently, there has been 
increasing appreciation for a largely understudied variable in CRC, the gut microbiome.  
This collection of symbiotic microorganisms inhabits the gastrointestinal tract and is 
associated with diseases such as obesity and inflammatory bowel disease [Turnbaugh 
et al., 2006; Manichanh et al., 2006].  In animal studies, evidence suggests that through 
interaction with the immune system, production of cancer-associated metabolites, and 
the release of genotoxic virulence factors, bacteria can directly contribute to the 
development of CRC [Zackular et al., 2013; Arthur et al., 2012; Couturier-Maillard et al., 
2013; Kostic et al., 2013].   Furthermore, in human studies, patients with CRC have an 
abnormal gut microbiome structure when compared to healthy patients [Chen et al., 
2013; Kostic et al., 2012; Geng et al., 2013; Shen et al., 2010; Sobhani et al, 2011; 
Wang et al., 2012; Ahn et al., 2013].  Taken together, this suggests that the gut 
microbiome might be a candidate biomarker for early detection of CRC. 
We hypothesized that using novel microbiome biomarkers of CRC in concert with 
known clinical risk factors could improve the ability to identify candidates for 
colonoscopy.  We compared the microbiome of healthy individuals, persons with 
adenomas, and patients with colorectal carcinomas.  We sequenced the V4 region of 
the 16S rRNA gene from the feces of each individual using the Illumina MiSeq 
sequencing platform.  The resulting data were used to test our hypothesis that the 
incorporation of microbiome data would significantly improve the ability to distinguish 
among the three types of individuals, beyond clinical (demographic) data and FOBT 
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results.  This analysis demonstrates that the microbiome provides a powerful source of 







Table 2.1. Characteristics of subjects in each clinical group.  Breakdown of clinical 
data from each of the clinical groups.  Body mass index (BMI) was calculated based on 
height and weight (kg/m2). 
 Healthy Adenoma Cancer P-value 
Age, years (mean, SD) 55.3 (9.2) 61.3 (11.1) 59.4 (11.0) 0.080 
     
Gender (n, %):  Men 11 (37%) 18 (60%) 21 (70%)  
                         Women 19 (63%) 12 (40%) 9 (30%) 0.029 
     
Race/Ethnicity: Non-Hispanic white 21 (70%) 27 (90%) 28 (93%)  
                         Other 9 (30%) 3 (10%) 2 (7%) 0.026 
     
Body mass index (mean, SD) 26.6 (5.2) 27.4 (4.4) 30.7 (7.2) 0.022 
     
Current medication use (n, %) 23 (77%) 21 (70%) 26 (87%) 0.295 
     





Selection of Subjects 
Colonoscopies were performed and fecal samples were collected from subjects 
in 4 locations: Toronto (Ontario, Canada), Boston (Massachusetts, USA), Houston 
(Texas, USA), and Ann Arbor (Michigan, USA).  All participants collected a whole 
evacuated stool after following the usual dietary and medication restrictions for 24 
hours.  Following endoscopic examination, patients without colonic abnormalities were 
designated as healthy (n=30). Examinations that revealed the presence of lesions 
resulted in a biopsy and subsequence diagnosis of adenoma (n=30) or carcinoma 
(n=30).  For each patient, clinical data were collected including demographic information 
and the results of the gFOBT (Table 2.1).  There were no significant differences in age 
or current medication use among the three patient groups.  However, among our 
samples, men, whites, and those with greater BMI were more likely to have colorectal 
cancer (Table 1).   
Comparison of healthy and adenoma clinical groups 
We utilized logit regression models to differentiate between patients in the 
healthy and adenoma clinical groups.  Preliminary models were generated using age, 
gender, race/ethnicity, BMI, and medication use as independent variables.  For these 
subjects, both age and race were significantly associated with the presence of 
adenomas (AUC=0.713; 95% CI: 0.580-0.845; p=0.009).  There were also differences in 
the gut microbiome between individuals with and without adenomas. Relative to healthy 
subjects, subjects with adenomas had higher relative abundances of operational 
taxonomic units (OTUs) affiliated with the Ruminococcaceae (OTUs 21 and 60) and 
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Porphyromonadaceae (OTUs 1901 and 1903); they had lower relative abundances of 
OTUs affiliated with the Bacteroides (OTUs 1889 and 1913), Lachnospiraceae (OTU 
36), Clostridiales (OTU 38), and Clostridium (OTUs 20, 97, 99) (Figure 2.1).  The model 
that yielded the greatest differentiation between adenoma and healthy groups included 
age, race, and 5 OTUs (OTUs 38, 99, 136, 1889, 1913) (Figure 2.2A).  The addition of 
these 5 OTUs significantly improved the predictive ability of the model beyond that of 
age and race only (AUC=0.896; 95% CI: 0.816-0.976; p=0.002) (Figure 2.2B).  These 
results demonstrate that differences in the gut microbiome could be detected at pre-
cancerous stages of CRC development and this signal may improve our ability to 







Figure 2.1. Microbial biomarkers for healthy and adenoma clinical groups. OTUs 
that were differentially abundant in healthy and adenoma clinical groups.  LDA scores 
for significant OTUs are shown.  OTU number and Taxonomic group based on RDP 
classification are represented.   
  





























Figure 2.2.  Microbiome improves accuracy of predictive models for healthy and 
adenoma. A. Relative abundance of differentially abundant OTUs for all healthy (n=30; 
grey) and adenoma (n=30; black) subjects. Vertical black line represents mean.  B. 
ROC curves for microbial biomarkers alone, clinical data alone, and microbial 
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Comparison of healthy and carcinoma clinical groups 
Next, we generated logit models using clinical and microbiome data to 
differentiate between patients in the healthy and carcinoma groups.  Age, race, and BMI 
were predictive of carcinomas (AUC=0.798; 95% CI: 0.686-0.910; p<0.001).  We 
observed that relative to healthy subjects, subjects with carcinomas had higher 
abundances of OTUs associated with Fusobacterium (OTU 2458), Porphyromonas 
(OTU 1905), and Enterobacteriaceae (OTU 2479); they had lower relative abundances 
of OTUs affiliated with the Bacteroides (OTU 1889), Lachnospiraceae (OTUs 23, 30, 
253, 136), and Clostridiales (OTU 42) (Figure 2.3).  To test the hypothesis that the gut 
microbiome could improve our ability to predict the presence of carcinomas, we added 
these OTUs to the logit model we generated based on the subjects’ age, race, and BMI 
(Figure 2.4B).  The model with the greatest discriminatory ability included age, race, 
BMI and 6 OTUs (OTUs 136, 1901, 1905, 1913, 2479, 2458; Figure 2.4A).  This model 
significantly improved the ability to distinguish between healthy and carcinoma 
compared to the model containing age, race and BMI only (AUC=0.922; 95% CI: 0.858-
0.986; p=0.012; (Figure 2.4B).  These results suggest that the relative abundance of six 
bacterial populations differentiate healthy gut tissue from the presence of cancerous 






Figure 2.3. Microbial biomarkers for healthy and carcinoma clinical groups. OTUs 
that were differentially abundant in healthy and carcinoma clinical groups.  LDA scores 
for significant OTUs are shown.  OTU number and Taxonomic group based on RDP 
classification are represented.   
 
  



































Figure 2.4  Microbiome improves accuracy of predictive models for healthy and 
carcinoma. A. Relative abundance of differentially abundant OTUs for all healthy 
(n=30; grey) and carcinoma (n=30; black) subjects.  Vertical black line represents mean. 
B. ROC curves for microbial biomarkers alone, clinical data alone, and microbial 
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Comparison of healthy individuals to those with colonic lesions  
Next, we explored the ability of the gut microbiome to differentiate between 
healthy subjects and those with either adenoma or carcinomas.   Thus, we combined 
the clinical and microbiome data from adenoma and carcinoma subjects to create a 
combined colonic lesion group.  We then generated a logit model to differentiate 
between healthy subjects and the colonic lesion group.  Clinical variables that were 
predictive of colonic lesion were age, gender, and race (AUC=0.754; 95% CI: 0.648-
0.859) (Figure 2.6).  To test the hypothesis that the gut microbiome could improve our 
ability to predict the presence of colonic lesions regardless of stage, we added 6 OTUs 
(OTU 136, 253, 1889, 1897, 1913, 2891) (Figure 2.5) to this logit model.  Age, gender, 
race, and these 6 OTUs significantly improved the ability to distinguish between the 
healthy and colonic lesion combined groups (AUC=0.936; 95% CI: 0.887-0.985; 
p<0.0001) (Figure 2.6).  These results demonstrate that the gut microbiome can 
improve the ability to discriminate between healthy subjects and colonic lesions 





Figure 2.5. Microbial biomarkers for healthy and colonic lesion clinical groups. 
OTUs that were differentially abundant in adenoma and carcinoma clinical groups.  LDA 
scores for significant OTUs are shown.  OTU number and Taxonomic group based on 
RDP classification are represented.  
  





























Figure 2.6. Microbiome improves accuracy of predictive models for healthy and 
colonic lesions. A. Relative abundance of differentially abundant OTUs for healthy 
(n=30; grey) subjects and those with lesions (n=60; black). Vertical black line represents 
mean. B. ROC curves for microbial biomarkers alone, clinical data alone, and microbial 
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Comparison of adenoma and carcinoma clinical groups 
Finally, we generated logit models using clinical and microbiome data to 
differentiate between patients in the adenoma and carcinoma groups.  A patient’s BMI 
was the only clinical variable that discriminated between the adenoma and carcinoma 
clinical groups (AUC=0.658; 95% CI: 0.518-0.799; p=0.023).  When examining 
populations within the gut microbiome, relative to subjects with adenomas, those with 
carcinomas harbored higher relative abundances of OTUs that affiliated with the 
Fusobacterium (OTU 2458), Bacteroides (OTU 1882), Phascolarctobacterium (OTU 
2395), and Porphyromonas  (OTU 1905).  In contrast, OTUs affiliated with Blautia (OTU 
9), and Lachnospiraceae (OTU 12 and 23) were more abundant in subjects with 
adenomas (Figure 2.7).  Next, we constructed a logit model to differentiate between the 
adenoma and carcinoma clinical groups using BMI with microbiome data.  The model 
that provided the greatest differentiation between carcinoma and adenoma included 
BMI and 4 OTUs (OTUs 1905, 2395, 2458, 3235; Figure 2.8A).  This model provided 
significantly greater discrimination than BMI alone (AUC=0.963; 95% CI: 0.921-1.00; 
(p<0.001; Figure 2.8B).  Examination of the relative abundance of OTUs associated with 
the Fusobacterium genera revealed no significant associations between Fusobacterium 
and the stage or location of carcinomas.  Together, these results demonstrated that the 
gut microbiome could be used to differentiate between the presence of precancerous 






Figure 2.7. Microbial biomarkers for adenoma and carcinoma clinical groups. 
OTUs that were differentially abundant in adenoma and carcinoma clinical groups.  LDA 
scores for significant OTUs are shown.  OTU number and Taxonomic group based on 
RDP classification are represented.   
  

































Figure 2.8. Microbiome improves accuracy of predictive models for adenoma and 
carcinoma. A. Relative abundance of differentially abundant OTUs for adenoma (n=30; 
grey) and carcinoma (n=30; black) subjects.  Vertical black line represents mean.  B. 
ROC curves for microbial biomarkers alone, clinical data alone, FOBT alone, microbial 
biomarkers with clinical data, and microbial biomarkers with FOBT and clinical data.  
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Complementing gFOBT test with microbiome-based models 
Because gFOBT is the most common, non-invasive screening tool for CRC, we 
evaluated whether the microbiome-based models could be improved by including 
gFOBT results.  The gFOBT test had 100% specificity in our study when comparing 
healthy individuals to those with colonic lesions.  That is, patients without colonic lesions 
tested negative on the gFOBT.  In an analysis comparing adenoma and carcinoma 
groups, the odds ratio for gFOBT was 3.76 (95% CI 1.04-13.65) when entered as a 
single explanatory variable, with AUC=0.617.  In contrast, the microbiome data alone 
yielded an AUC of 0.952.  The model combining BMI, gFOBT, and the microbiome data 
(OTUs 1905, 2395, 2458, 3235) provided excellent discriminatory ability (AUC=0.969; 
95% CI: 0.935-1.000; Figure 2.8B). These results demonstrate that the gut microbiome 
dramatically outperforms gFOBT in discriminating between adenoma and carcinoma 
clinical groups in our sample of subjects. 
Application of Microbiome Results to Population Data 
To further test the capacity of the gut microbiome as a CRC screening candidate, 
we extracted data from Surveillance, Epidemiology and End Results (SEER) for age-
specific incidence rates of CRC in the United States. Since likely candidates for CRC 
screening would target identification of early stage disease (adenoma), we designed a 
preliminary screening test based on the 5 OTUs (OTUs 38, 99, 136, 1889, 1913), which 
were enriched in healthy subjects compared to patients with adenomas.  Persons who 
had any detectable levels (Relative abundance > 0) of these 5 OTUs were more likely to 
have healthy colons and constituted a negative test.  Using a Bayesian model, we 
calculated the positive likelihood ratio for this preliminary screening test and applied it to 
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population probabilities of CRC for each age group (Table 2.2).  The likelihood ratio of 
this test was 71 (95% CI: 64.78, 77.22) (sensitivity=23.3% [7/30], specificity=100% 
[30/30]).  As can be seen in Table 2.2, individuals who are 65 years of age had a pre-
test probability of CRC of 0.17% based on nationwide SEER data.  When we applied 
the OTU test to this age group, the probability of adenoma was 10.67% after knowing 
the microbiome data (1 in 9 chance of having an adenoma).  For people 50 years of 
age, the results suggest a one in 26 chance of having an adenoma with a positive OTU 
test, and for adults 80 years of age; a positive OTU test yielded a 1 in 5 chance of 
having an adenoma. Together, these results demonstrate that our preliminary screen 
dramatically improves the ability to predict the presence of an adenoma. 
For comparison purposes, we assessed the pre-to-post-test probabilities of 
detecting adenoma based on the gFOBT results in this sample.  The likelihood ratio of a 
positive gFOBT was 41 (95% CI: 34.75 - 47.25), which was lower than the likelihood 
ratio of a positive microbiome test (i.e., LR+=71).  For a person who is 65 years of age 
with a positive gFOBT, the post-test probability of adenoma was 6.46%, indicating a 1 in 
15 chance of having an adenoma.  This contrasts with the 10.67% probability of 
adenoma (1 in 9 chance) using a positive microbiome test in the same 65-year 
old.  While both tests had good specificity in this sample, the sensitivity of the 




* Based on Surveillance, Epidemiology and End Results data, Years 2000-2010. 	  
** Using Likelihood Ratio of a positive test = 71.   	  
 
Table 2.2. Post-test probability of microbiome-based adenoma screen.  The 
probability of having an adenoma is listed for each age group prior to and after the 
incorporation of the results of a preliminary screen test based on microbiome relative 



















35-39 8.20 0.0001 0.0001 0.0058 0.0058 0.005-0.006 
40-44 15.78 0.0002 0.0002 0.0112 0.0111 0.010-0.012 
45-49 29.11 0.0003 0.0003 0.0207 0.0203 0.019-0.023 
50-54 55.81 0.0006 0.0006 0.0396 0.0381 0.036-0.043 
55-59 76.99 0.0008 0.0008 0.0547 0.0519 0.045-0.060 
60-64 112.05 0.0011 0.0011 0.0796 0.0738 0.073-0.087 
65-69 168.04 0.0017 0.0017 0.1195 0.1067 0.109-0.130 
70-74 223.40 0.0022 0.0022 0.1590 0.1372 0.145-0.173 
75-79 283.25 0.0028 0.0028 0.2017 0.1678 0.184-0.219 
80-84 337.10 0.0034 0.0034 0.2401 0.1936 0.219-0.261 





Our results suggest that relative abundance data from the human gut microbiome 
differentiates individuals with healthy colons from those with adenomas and 
carcinomas.  Most importantly, there was a significant difference in the gut microbiome 
of people with colonic adenomas compared to those with healthy colons.  This has 
considerable importance in secondary prevention because screening for early stage 
colorectal cancer hinges on the ability to detect early pathologic changes.  In this 
regard, we found that failure to detect at least 1 of the 5 OTUs served as a signal of the 
presence of adenoma.  The probability of having an adenoma rose over 50-fold with this 
added information regarding microbiome.  Taken with the existing literature regarding 
the importance of the gut microbiome in health and disease, our study further suggests 
that the microbiome may play a crucial role in the etiology of colorectal cancer. 
A strength of our study design was that we collected samples from three clinical 
groups that represented the multistage progression in CRC (healthy, adenoma, and 
carcinoma).  This allowed us to identify a panel of bacterial populations that could 
indicate both the progression from healthy tissue to adenoma and the progression from 
adenoma to carcinoma.  Interestingly, when we looked at each patient, we rarely 
observed significant enrichment of every bacterial population among the OTUs 
incorporated in the logit models.  For example, 11 of the 30 carcinoma patients had no 
detectable levels of Fusobacterium.  However using the relative abundance data for the 
remaining panel of microbial biomarkers, such as Porphyromonas, Bacteroides, and 
Enterobacteriaceae, we were able to accurately classify these subjects.  This strongly 
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suggests that there may be multiple underlying mechanisms by which the microbiome is 
involved in CRC and that CRC is likely a polymicrobial disease. 
Our findings are supported by previous evidence.  Three research groups 
reported that Fusobacterium spp. were enriched on the surface of tumors compared to 
adjacent healthy tissue [Kostic et al., 2012; Castellarin et al., 2012; Rubinstein et al., 
2013].  Building upon these clinical studies, animal and tissue culture-based studies 
have provided evidence that Fusobacterium may contribute to tumor multiplicity through 
the recruitment of immune cells to tumors [Kostic et al., 2013; Rubinstein et al., 2013].  
These mechanistic studies agree with our findings that Fusobacterium may be a marker 
for the presence of tumors.  In addition, enterotoxigenic Bacteroides fragilis (ETBF), a 
pathogenic variant of a common commensal, has been shown to directly influence the 
development of CRC in murine genetic models through the production of a 
metalloprotease toxin [Sears et al., 2008].  In our samples, subjects with carcinomas 
showed an increase in the relative abundance of one Bacteroides population (OTU 
1882) compared to subjects with adenomas. However, PCR-based screens for the toxin 
producing genes did not reveal the presence of ETBF.  Additionally, we observed a 
significant decrease in the relative abundance of Bacteroides populations (OTUs 1889, 
1913) associated with the advancement of tumorigenesis. Finally, a polyketide 
synthetase operon from E. coli, was shown to influence the progression of tumors using 
a murine model of inflammation-derived tumorigenesis [Arthur et al., 2012, Swidsinski et 
al., 1998].  Although we did see an enrichment for non-E. coli Enterobacteriaceae in the 
carcinoma subjects relative to the healthy subjects, we were unable to detect significant 
differences in the relative abundance of E. coli across the three clinical groups.  
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It is tempting to speculate on the enrichment of Fusobacterium and 
Porphyromonas spp. in subjects with CRC.  Both of these bacterial taxa are common 
commensals of the mouth and a wealth of literature has linked them to chronic 
inflammation and periodontal disease [Signat et al., 2011; Deshpande et al., 1999; 
Darveau and Tanner, 1997; Han et al., 2000].  The mouth is a reservoir for these 
pathogens, allowing for colonization of the gastrointestinal tract under abnormal 
environmental conditions.  During colorectal carcinogenesis, dramatic physiological 
changes occur in the microenvironment of colonic lesions [Peddareddigari et al., 2010].  
Tumor-associated fluxes in nutrients and shifts in inflammatory mediators may favor 
colonization by opportunistic pathogens such as Fusobacterium and Porphyromonas.  
As demonstrated by Kostic and colleagues, colonization by such pathogens can support 
the development and progression of CRC [Kostic et al., 2013,Rubinstein et al., 2013].  
We were unable to detect a significant association between either population and 
carcinoma severity or location.  Additional studies are needed to examine how and at 
what stage these bacterial populations are affecting the development of CRC and how 
they may be linked to the oral microbiome and related to oral disease.   
As highlighted above, there is a clear association with the enrichment of 
pathogenic bacterial populations and colon tumorigenesis; however, in the present 
study we emphasize that the depletion of potentially protective bacteria likely plays a 
similar role CRC pathology.  We identified several bacterial populations that were 
significantly depleted in CRC.  Individuals with both adenomas and carcinomas showed 
a dramatic loss in OTUs associated with the genera Clostridium and Bacteroides, and 
the family Lachnospiraceae [Atarashi et al., 2011; Smith et al., 2013; Round et al., 
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2010].  Each of these bacterial taxa are well known producers of short chain fatty acids 
(SCFAs) in the colon.  SCFAs are important microbial metabolites that supply nutrients 
to colonocytes and help maintain epithelial health and homeostasis.  Specifically the 
SCFA, butyrate, has been shown to have substantial anti-tumorigenenic properties 
including the ability to inhibit tumor cell proliferation, initiate apoptosis in tumor cells 
[Hague et al., 1995; Ruemmele et al., 2003], and mediate T-regulatory cell homeostasis 
[Smith et al., 2013].  Loss of these important bacterial populations in concert with an 
enrichment of pathogenic populations likely plays a synergistic role in potentiating 
tumorigenesis.  
Although our results are important, there are limitations to the investigation.  A 
larger, more diverse sample of individuals is needed to augment and validate our 
findings.  Furthermore, although our study clearly demonstrates the viability of using the 
gut microbiome as a biomarker for CRC, we cannot assess the bacterial populations’ 
role in causation or the mechanisms by which these populations affect the development 
and progression of CRC.  Regardless, the feasibility, lack of invasive procedures, ability 
to be complement existing screening methods (e.g. gFOBT), and the strength of signal 
seen in this study support the further investigation and application of microbial 




Material and Methods 
Study design and sample collection 
As part of the National Cancer Institute-funded Early Detection Research 
Network (EDRN), the Great Lakes-New England Clinical Epidemiological Center (GLNE 
CEC) created a biorepository that included whole evacuated stool for studies on 
potential molecular markers for the detection of colonic precancerous and cancerous 
conditions and cancer risk assessment.  Eligible patients were 18 years of age or older, 
able to tolerate 58 ml of blood removal at two time points, willing to complete an gFOBT 
kit, able to provide informed consent, and had colonoscopy and histologically confirmed 
colonic disease status.  Patients were excluded if known HIV or chronic viral hepatitis, 
known HNPCC or FAP, inflammatory bowel disease, any surgery, radiation or 
chemotherapy for their current colorectal cancer or colonic adenoma. Colonic disease 
status was defined as normal (no personal or family history of colon cancer, adenomas), 
colonic adenoma (colonoscopic and histologically confirmed adenoma), and colorectal 
adenocarcinoma (colonoscopic and histologically confirmed colorectal 
adenocarcinoma). 
All participants collected a whole evacuated stool in a hat with no preservatives.  
Immediately after collection, the patient prepared a gFOBT six-panel kit (Sensa 
Hemocult II, Beckman-Coulter, Palo Alto, CA) from different areas of the stool.  The 
whole stool was then packaged and shipped to the processing center along with the 
gFOBT.  The gFOBT was processed and interpreted as soon as it arrived at the 
processing center.  If any of the six wells were positive, the kit was recorded as positive 
for the participant.  The whole stool was homogenized and aliquoted into equal volumes 
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and stored at -800C.  All participants had intact colonic lesions at time of stool collection.  
Study participants provided their stool sample between one and four weeks after their 
colonoscopy preparation.  We were provided with 90 stool samples and linked data 
randomly chosen from disease groups of healthy (n=30), colonic adenoma (n=30), and 
colonic adenocarcinoma (n=30).   
 
DNA extraction and 16S rRNA gene sequencing 
Microbial genomic DNA was extracted using the PowerSoil-htp 96 Well Soil DNA 
isolation kit (Mo Bio Laboratories) using an EPMotion 5075 pipetting system.  The V4 
region of the 16S rRNA gene from each sample was amplified and sequenced using the 
Illumina MiSeq Personal Sequencing platform as described elsewhere [Kozich et al., 
2013].  Sequences were curated as described previously using the mothur software 
package [Schloss et al., 2009].  Briefly, we reduced sequencing and PCR errors, 
aligned the resulting sequences to the SILVA 16S rRNA sequence database [Pruesse 
et al., 2007], and removed any chimeric sequences flagged by UCHIME [Edgar et al., 
2011].  After curation, we obtained between 25,953 and 404,696 sequences per sample 
(median=95464), with a median length of 253 bp.  To limit effects of uneven sampling, 
we rarefied the dataset to 25,958 sequences per sample.  Parallel sequencing of a 
mock community revealed an error rate of 0.03%.  All fastq files and the MIMARKS 
spreadsheet are available at http://www.mothur.org/MicrobiomeBiomarkerCRC. 
 
Gut Microbiome Biomarker Discovery Analysis 
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Sequences were clustered into OTUs at a 97% similarity cutoff and the relative 
abundance was calculated for OTUs in each sample.  All sequences were classified 
using a naïve Bayesian classifier trained against the RDP training set version 9 
(http://sourceforge.net/projects/rdp-classifier/) and OTUs were assigned a classification 
based on which taxonomy had the majority consensus of sequences within a given OTU 
[Wang et al., 2007].  Differentially abundant OTUs were selected using the biomarker 
discovery algorithm, LEfSe (Linear discriminant analysis Effect Size) for each pairwise 
comparison of clinical groups [Segata et al., 2011] (Healthy vs. Adenoma, Healthy vs. 
Carcinoma, Adenoma vs. Carcinoma, Healthy vs. Colonic lesion) using a maximum P-
value of 0.05 and a minimum linear discriminant analysis (LDA) score of 2.0. 
 
Data Analyses 
Analyses of patient-level characteristics across the three clinical groups utilized 
Pearson chi-square test for categorical data and one-way ANOVA for continuous 
variables.  Clinical variables evaluated were age, gender, race/ethnicity, body mass 
index (BMI, kg/m2), and current medications.  One missing value for BMI was imputed. 
Logit models were generated using both clinical and microbiome data as independent 
variables to contrast differences across disease groups (i.e., healthy versus adenomas; 
healthy versus cancer; adenomas versus cancer).  OTUs demonstrating the highest 
LDAs and smallest p-values were entered into a logit model and their ability to 
discriminate group classification was evaluated using area under the receiver operator 
characteristic (ROC) curve.  We used a maximum of 6 OTUs for each model to avoid 
potentially over-fitting the model.  Differences between nested models were compared 
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using the test for the equality of ROC areas [Delong et al., 1988].  Data were available 
on gFOBT status and therefore, this was entered as an independent variable when 
comparing adenoma versus carcinoma.  We tested using an experiment wide error rate 
(i.e. α) of 0.05 and performed 2-tailed tests.  Analyses were conducted in Stata/MP 
13.1. 
We utilized Bayesian methods to estimate the probability of adenoma based on 
relative abundance data taken from the gut microbiome [Linnet, 1988].  We utilized data 
from the 5 OTUs found to differentiate adenoma from healthy colons as the basis of a 
preliminary screening test. Sensitivity, specificity and positive likelihood ratios were 
calculated based on our study results, with failure to detect any appreciable level of any 
of these 5 OTUs (0 relative abundance) indicating possible pathology (i.e., positive test).  
Since the false positive rate of this test was 0%, we applied a continuity correction of 0.1 
to each cell and calculated the likelihood ratio of a positive test and the 95% confidence 
intervals using standard methods [Simel et al., 1991].  The likelihood ratio was then 
applied to the pre-test probability of CRC based on national Surveillance, Epidemiology 
and End Results (SEER) data, years 2000-2010. 
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Recent studies have shown that individuals with colorectal cancer have an 
altered gut microbiome when compared to healthy controls.  It remains unclear whether 
these differences are a response to tumorigenesis or actively drive tumorigenesis.  To 
determine the role of the gut microbiome in the development of colorectal cancer, we 
characterized the gut microbiome in a murine model of inflammation-associated 
colorectal cancer that mirrors what is seen in humans.  We followed the development of 
an abnormal microbial community structure associated with inflammation and 
tumorigenesis in the colon.  Tumor-bearing mice showed enrichment in operational 
taxonomic units (OTUs) affiliated with members of the Bacteroides, Odoribacter, and 
Turicibacter genera, and decreases in OTUs affiliated with members of the 
Prevotellaceae and Porphyromonadaceae families. Colonization of germ-free mice with 
microbiota from tumor-bearing mice significantly increased tumorigenesis in the colon 
compared to animals colonized with a healthy gut microbiome from untreated mice.  
Furthermore, at the end of the model, germ-free mice colonized with microbiota from 
tumor-bearing mice harbored a higher relative abundance of populations associated 
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with tumor formation in conventional animals.  Manipulation of the gut microbiome with 
antibiotics resulted in a dramatic decrease in both the number and size of tumors.  Our 
results demonstrate that changes in the gut microbiome associated with inflammation 
and tumorigenesis directly contribute to tumorigenesis and suggest that interventions 
affecting the composition of the microbiome may contribute to a strategy to prevent the 




Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies 
worldwide, resulting in over a half million deaths annually [Parking et al., 2005].  
Significant risk factors for CRC include diets rich in red and processed meat, alcohol 
consumption, and chronic inflammation of the gastrointestinal tract [Chambers et al., 
2005; Huxley et al., 2009; Larsson et al., 2005; Slattery, 2000]. Each of these factors is 
closely associated with changes in composition and function of the complex community 
of microorganisms that inhabits our gastrointestinal tract.  This community, known as 
the gut microbiome, promotes various physiological functions that are associated with 
cancer, including cell proliferation, angiogenesis, and apoptosis [Cheesman et al., 2011; 
Dolara et al., 2002; Stappenbeck et al., 2002; Rakoff-Nahoum et al., 2007].  Therefore, 
we hypothesized that the composition, structure, and functional capacity of the gut 
microbiome all directly affect tumor development in the colon.   
Several recent studies have addressed this hypothesis by characterizing the 
composition of the gut microbiome associated with patients with CRC [Chen et al., 
2013; Chen et al., 2012; Kostic et al., 2012; Geng et al., 2013; Shen et al., 2010; 
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Sobhani et al., 2011; Wang et al., 2012].  Using culture-independent approaches, each 
of these studies observed a significant shift in the composition of the gut microbiome in 
patients with CRC when compared to healthy controls.   This phenomenon referred to 
as dysbiosis, can be observed in both the luminal microbiome from feces and the 
mucosal-associated microbiome from tumor biopsies.  Interestingly, each of these 
studies obtained conflicting results regarding the composition and structure of the CRC-
associated microbial community.  Furthermore, there are no bacterial populations that 
have been consistently identified across each study that can be attributed to the 
development or presence of CRC.  These data clearly show an association between 
abnormalities in the gut microbiome and CRC; however, the conflicting results point out 
the need for a mechanistic understanding of the role of the gut microbiome in this 
process. 
The combination of factors that could lead to dysbiosis is complex and not well 
understood.  In addition, the effect of the development of this abnormal community on 
colon tumorigenesis remains unclear.  Recent evidence suggests that certain strains of 
Bacteroides fragilis and E. coli can directly affect tumor development in the colon 
through the production of virulence factors (e.g. toxins, gene products) [Arthur et al., 
2012; Wu et al., 2009].  Furthermore, bacterial populations that produce the short chain 
fatty acid, butyrate, have anti-tumor effects in the colon by promoting apoptosis of 
colonic cancer cells [Hague et al., 1995; Ruemmele et al., 2003].  We reason that 
dysbiosis of the gut microbiome leads to both enrichment of cancer-promoting bacterial 
populations and loss of protective populations.  Thus, understanding the changes in the 
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gut microbiome on a community-wide scale will be essential for understanding colon 
tumor development. 
The gut microbiome is also likely to contribute to CRC through the initiation of 
inflammation.  The link between inflammation and cancer is well established, and 
patients with inflammatory bowel diseases, such as ulcerative colitis, are at a greater 
risk of developing CRC in their lifetime. In the case of ulcerative colitis, the risk for 
cancer is related to both duration and severity of inflammation with an increasing rate of 
0.5-1% per year after the first decade [Chambers et al., 2005; Ullman et al., 2011; 
Eaden et al., 2000].  Chronic inflammation of the colon leads to the production of 
various inflammatory cytokines and reactive oxygen species that work in concert to 
generate a tumor microenvironment that promotes carcinogenesis [Ullman et al., 2011; 
Arthur et al., 2013; Lin et al., 2007].  It has been suggested that this process is 
microbially driven, but it is unclear how the no rmally beneficial gut microbiome 
becomes inflammatory. 
To determine the role of the gut microbiome in inflammation and colon 
tumorigenesis, we used a well-established model of colitis-associated CRC that 
recapitulates the progression from chronic inflammation to dysplasia and 
adenocarcinoma in humans [De Robertis et al., 2011]. We characterized the dynamics 
of the gut microbiome in this model and demonstrated that community-wide changes 
promote tumorigenesis in the colon.  Our data support a model in which epithelial cell 
mutation and inflammatory perturbations to the gut microbiome lead to the development 





Inflammation-associated colon tumorigenesis.   
We were able to replicate an inflammation-based murine model of tumorigenesis 
in specific pathogen free (SPF) C57BL/6 mice (n=22) using an intraperitoneal injection 
of the chemical carcinogen azoxymethane (AOM) followed by three subsequent rounds 
of water-administered 2% dextran sodium sulfate (DSS) treatment [Tanaka et al., 2003; 
Chen et al., 2008] (Figure 3.1).  The mice showed a consistent pattern of weight loss 
following each round of DSS treatment, with the most pronounced change occurring 
after the first round of DSS (Figure 3.2).  We did not observe macroscopic tumors 
following the first round of DSS administration; however, we did observe increased 
infiltration by immune cells, significant epithelial damage, and submucosal edema 
(Figure 3.2).  In addition, we observed a significant increase in the pro-inflammatory 
mediators macrophage inflammatory protein 2 (MIP-2), interferon gamma (IFN-γ), tumor 
necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and IL-1β (Figure 3.2).  Macroscopic 
tumors and epithelial hyperplasia were apparent following the second round of DSS 
(Figure 3.1B, Figure 3.2).  At the end of the model, the cohort had a median of 14.5 
tumors per mouse (n=12), the majority of which were greater than 1 mm in diameter and 
located in the distal colon and rectum (Figure 3.2).   These results demonstrate that our 
cohort of AOM/DSS treated mice developed a substantial number of colonic tumors with 
complete penetrance that could be detected as early as 7 weeks after AOM injection. 
To determine whether tumor incidence and penetrance was dependent on the 
gut microbiome, we treated mice (n=9) with an antibiotic cocktail of metronidazole, 
vancomycin, and streptomycin ad libitum for 2 weeks prior to AOM and then throughout 
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the model, including the days of AOM injection and throughout the DSS treatment and 
recovery periods.   Antibiotic-treated mice had significantly fewer tumors in the colon 
relative to the untreated mice (Fisher exact test: p<0.001; Fig. 3.1B).  Tumors that were 
present in antibiotic-treated mice were also significantly smaller than those observed in 
untreated mice (Student’s t-test: p=0.002; Fig. 3.1C, Figure 3.8).  These results suggest 
that specific populations within the microbiome were essential for tumorigenesis.  To 
determine whether the relative change in bacterial density following antibiotic treatment 
was due to a change in bacterial load, we performed qPCR on the 16S rRNA gene from 
stool samples of antibiotic-treated mice. The number of 16S rRNA gene copies per mg 
of feces was not significantly different from untreated stool samples (p=0.21, Figure 
3.6).  Combined, these results indicate that changes to the structure of the community 








Figure 3.1.  Development of a dysbiotic gut microbiome during colon 
tumorigenesis.  Microbiome analysis was performed on fecal samples from 10 
representative mice and color coded as indicated in Figure 3.1A.  A. Inverse Simpson’s 
diversity index.  B.  Observed community richness estimate.  Statistical analysis was 
performed using repeated measured paired group analysis of variance. C. NMDS 
ordination based on θyc distances for all 10 mice during the AOM/DSS model.  (AMOVA; 
P < 0.01) D.  Average θYC distance within (black) and between (grey) phase of the 
model.  Statistical analysis was performed using Wilcoxon test.  *, P < 0.01.  Error bars  








Figure 3.2. Colonic inflammation during tumorigenesis. A. Relative cytokine 
expression levels in colon. Statistical analysis was performed using a two-tailed 
Student’s t-test.  *, P < 0.01.  B.  Representative H&E stained histological sections from 
colon of mice during AOM/DSS tumor induction protocol.   Single arrows indicate 
mucosal ulceration, double arrows indicate submucosa edema, and dashed arrows 

































































































Significant shifts in the microbiome are associated with colon tumorigenesis.  To 
further test the hypothesis that specific changes in the microbial community structure 
were associated with inflammation and tumorigenesis, we examined the dynamics of 
the gut microbiome throughout the model using stool samples from a subset of the 
original cohort of conventional mice treated with AOM/DSS in Figure 3.1 (n=10).  We 
used the fecal samples taken prior to AOM injection as a baseline control for each 
mouse and then took samples following each subsequent round of DSS administration 
(Figure 3.1A).  Mice showed a significant decrease in microbial diversity in the gut 
microbiome following the first round of DSS administration through tumor development 
(P<0.001; Figure 3.3A and 3.3B).  Ordination of the distances between fecal samples 
showed that at the time of euthanization, tumor-bearing mice developed a significantly 
altered microbiome that clustered separately from that in baseline samples taken prior 
to the first round of DSS (Figure 3.3C).  Further examination of fecal samples collected 
at various time points during the AOM/DSS tumor induction protocol revealed that 
significant alterations in the microbiome could be observed as early as the first round of 
DSS administration in 7 of the 10 mice.  Each round of DSS treatment resulted in a 
significant change in the structure of the microbiome (Figure 3.3D).   Fecal samples 
taken from tumor-bearing mice after the third round of DSS until the time of 
euthanization also clustered separately from earlier samples.  The distances between 
clusters were significantly higher than the distance within clusters (Figure 3.3D). These 
clusters were observed using OTU and phylogenetic-based metrics of β-diversity (i.e. 
ΘYC and unweighted or weighted UniFrac) and could be distinguished from one another 
using the Random Forest machine learning algorithm (Accuracy for each group: 
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Baseline: 100%, DSS round 1: 72.4%, DSS round 2: 71.9%, DSS round 3: 80.6%).  
These results highlighted the association between a dramatically altered microbiome 
structure and the presence of tumors.  
To determine the effect of inflammation on the microbial community independent 
of tumorigenesis, we treated mice with three rounds of DSS without the AOM injection 
(n=5). Mice treated with DSS in the absence of AOM did not develop colonic tumors. 
There was an initial community shift following the first round of DSS, but the subsequent 
stepwise shifts that occurred in AOM/DSS-treated mice were not observed in mice 
treated with DSS only (Figure 3.7).  Furthermore, we did not observe the sustained drop 
in microbial diversity that was observed in AOM/DSS-treated animals (Figure 3.7).  
These results suggest that inflammation alone is insufficient to cause microbial 
community changes.  Rather, the synergistic effects of the AOM/DSS model are 
necessary for the development of the altered microbiome structure and tumorigenesis. 
We next identified which operational taxonomic units (OTUs) were responsible for the 
dramatic shifts to the microbial community structure during inflammation and 
tumorigenesis (Figure 3.4).  Consistent with our communitywide β-diversity analyses, 
we observed changes in 37 bacterial populations (after excluding OTUs representing < 
0.5% of the community) during the time course of the model relative to baseline 
samples prior to treatment.  Fecal samples taken after the first round of DSS were 
enriched in the relative abundance of OTUs affiliated with members of the genus 
Bacteroides (OTUs 1 and 13).  We also observed significant decrease in the relative 
abundance of OTUs associated with members of the genus Prevotella and unclassified 
genera within the family Porphyromonadaceae.  Following the second round of DSS, we 
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observed a further loss of the same Prevotella (OTUs 4 and 5) and 
Porphyromonadaceae (OTUs 7, 12, 15, 22, 31, and 48) and the continued enrichment 
of Bacteroides (OTUs 1 and 13).  Samples taken from mice following the third round of 
DSS showed significant differences compared to those taken following the first round of 
DSS and healthy baseline mice (Figure 3.4; all P<0.001 by AMOVA).  Tumor-bearing 
mice showed enrichment in OTUs affiliated with Bacteroides (OTUs 1), Odoribacter 
(OTU 3), and Turicibacter (OTU 20).  Additionally, in tumor-bearing mice we detected a 
marked bloom of a member of the Erysipelotrichaceae family (OTU 26), which was 
undetectable in all of the mice prior to the second round of DSS when tumors are not 
evident.  Simultaneous with the blooming of several bacterial populations, there was a 
significant decrease in the relative abundance of OTUs associated with members of the 
genus Prevotella (OTUs 4 and 5) and the family Porphyromonadaceae (OTUs 7, 12, 15, 
22, 31, and 48). An OTU associated with the Bacteroides genus (OTU 13), which 
bloomed during the onset of inflammation, significantly decreased following the third 
round of DSS.  Mice that were treated with DSS in the absence of AOM, showed no 
significant changes in specific bacterial populations when compared to untreated mice. 
These results strongly suggest that both inflammation and tumorigenesis promote gut 
microbiome dysbiosis, as highlighted by major shifts in bacterial populations from a wide 





Figure 3.3.  Development of a dysbiotic gut microbiome during colon 
tumorigenesis.  Microbiome analysis was performed on fecal samples from 10 
representative mice and color coded as indicated in Figure 1A.  A. Inverse Simpson’s 
diversity index.  B.  Observed community richness estimate.  Statistical analysis was 
performed using repeated measured paired group analysis of variance. C. NMDS 
ordination based on θyc distances for all 10 mice during the AOM/DSS model.  (AMOVA; 
P < 0.01) D.  Average θYC distance within (black) and between (grey) phase of the 
model.  Statistical analysis was performed using Wilcoxon test.  *, P < 0.01.  Error bars 







Figure 3.4. Change in relative abundance for OTUs that are significantly different 
from the time of AOM administration. Heatmap shows change in OTU abundance 
relative to samples taken at baseline time points.  Average OTU abundance between 
mice for each OTU was calculated for each time point.  Timeline is colored into the 
following groups:  Baseline samples (prior to AOM): black, following the first round of 
DSS: blue, following the second round of DSS: green, Following the third round of DSS: 
red.  OTU number and Taxonomic group based on RDP classification are represented 
for each row and each OTU is colored based on phylum (Firmicutes: blue, 
Bacteroidetes: red, Tenericutes: black).  Repeated measures paired group analysis of 
variance was used to identify significantly altered OTUs.    
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We hypothesized that the variability in tumor burden among AOM/DSS-treated 
mice was associated with variability in the gut microbiome between mice (coefficient of 
variation for tumor burden=37.9; Figure 3.1C).  We identified an OTU related to an 
unclassified genus within the family Porphyromonadaceae (OTU 12) that was negatively 
correlated with tumor burden (Spearman correlation=-0.73, p-value<0.05).  The relative 
abundance of this bacterial population decreased with each round of DSS and this drop 
in abundance was more pronounced in mice with higher tumor burden.  These results 
suggest that alterations in the relative abundance of specific bacterial populations were 
associated not only with the incidence of tumors, but also their prevalence. 
 
Tumor-associated alterations in the microbiome increase tumorigenesis in germ-
free mice.   
To determine whether the community-wide microbiome changes directly 
contributed to tumor incidence in the colon, we colonized germ-free mice with either the 
healthy microbiome of untreated mice or the microbiome of tumor-bearing mice from 
Figure 3.1 following administration of the AOM/DSS model.  To ensure that mice were 
repeatedly inoculated and stably colonized, we transferred fresh feces and bedding to 
two groups of germ-free mice (n=10/group).  One group was housed with the bedding 
from healthy, untreated SPF mice, and a second group was housed with bedding from 
tumor-bearing AOM/DSS treated mice.  To minimize litter effects, each group was 
comprised of two cages of 5 mice collected from separate litters that were randomly 
assigned to each of the cages.  Following a three-week colonization period, mice were 
treated with AOM/DSS under germ-free conditions, as described above (Figure 3.1).  All 
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bacterial phyla and 90% (62 of 69) of genus-level taxa detected in donor samples were 
detected within the recipient germ-free mice (Table 3.2), which is higher than has been 
previously reported [Turnbaugh et al., 2009; Smith et al., 2013].  Furthermore, 81% of 
the sequences we obtained from the donor mice belonged to OTUs that were found in 
the recipient germ-free mice.  Following AOM/DSS treatment, mice colonized with the 
microbiome of tumor-bearing mice had a 2-fold increase in tumor burden (p=0.002) 
relative to mice colonized with a healthy microbiome (Figure 3.5).  Additionally, tumors 
from these mice were significantly larger than those observed in recipients of a healthy 
microbiome (p=0.002; 3.8).  Similar to our results with SPF mice, germ-free mice 
colonized with the community of tumor-bearing mice had a significantly less diverse gut 
microbiome (P<0.001).  Using community wide β-diversity analyses we determined that 
following a three-week colonization period with these two treatments of bedding resulted 
in two distinct microbial community structures (AMOVA; p<0.001; Figure 3.5C).  Germ-
free mice colonized with the microbiome of tumor-bearing mice showed significant 
enrichment in the relative abundance of OTUs affiliated with the genera Bacteroides 
(OTU 1) and the family Erysipelotrichaceae (OTU 26).  Additionally, these germ-free 
mice had significantly fewer Porphyromonadaceae (OTU 12) when compared to germ-
free mice colonized with bedding from healthy mice. Finally, germ-free mice colonized 
with a healthy microbiome successfully recapitulated the community dynamics seen in 
conventional mice during tumorigenesis. We observed significant changes in 34 OTUs 
following the AOM/DSS model.  Similar to tumor-bearing conventional mice, germfree 
tumor-bearing mice showed enrichment in OTUs affiliated with members of the 
Bacteroides (OTUs 1), Odoribacter (OTU 3), Turicibacter (OTU 20), and a bloom in 
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Erysipelotrichaceae (OTU 26), following AOM/DSS administration. There was also 
significant decrease in the relative abundance of OTUs associated with members of the 
genus Prevotella (OTUs 4 and 5) and the family Porphyromonadaceae (OTUs 6, 7, and 
12).  These results demonstrate that alterations to the gut microbiome that were 
associated with chronic inflammation and tumorigenesis in SPF mice were transmitted 







Figure 3.5.  Tumor-associated gut microbiome alterations exacerbate 
tumorigenesis in germ-free mice.   A.  Number of tumors observed at the end of the 
model when germ-free mice were colonized using bedding from healthy mice (Healthy 
community) and mice with tumors (Dysbiotic community).  Tumors counts were taken 
following AOM/DSS treatment.  B.  Representative images of tumors in the distal colon 
of mice colonized with a healthy microbiome (n=10) or the microbiome of tumor-bearing 
mice  (n = 9). C. NMDS ordination based on θyc distances for all 19 mice following a 
three-week colonization period with a healthy microbiome (Healthy community) or the 






In the present study we established a causal role for the gut microbiome in 
exacerbating tumor formation in an inflammation-based model of tumorigenesis.  
Manipulation of the microbiome using antibiotics reduced tumor formation, which 
highlighted the importance of bacterial driven factors in tumorigenesis.  We 
demonstrated dynamic changes in the microbial community structure associated with 
dysbiosis, which occurs prior to the first signs of macroscopic tumor formation.  We 
established the synergistic affect of AOM- and DSS-induced inflammation and 
tumorigenesis in driving microbial community changes that occur in a stepwise fashion.  
Finally, transfer of microbiota from tumor-bearing mice into germfree mice significantly 
increased the number and size of tumors compared to that in germ-free mice inoculated 
with healthy microbiota.  Our experiments also demonstrated dramatic shifts in the 
relative abundance of bacterial populations, including those related to the genus 
Bacteroides, which were associated with increased tumorigenesis. 
Several recent studies have compared the gut microbiome of patients with CRC 
to healthy controls [Chen et al., 2013; Chen et al., 2012; Kostic et al., 2012; Geng et al., 
2013; Shen et al., 2010; Sobhani et al., 2011; Wang et al., 2012].  These studies have 
consistently demonstrated significant differences in the microbial community structure of 
patients with CRC, but each study has disagreed in terms of the specific gut microbiome 
composition and profile associated with CRC.  The inability to identify a consensus 
community profile or etiological agent is likely due to the large variation in the structure 
of the microbiome across individuals and the improbability of there being one 
community profile or bacterial population that is associated with all CRCs.  We were 
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able to reduce the inter-individual variation and the diversity of cancer types using a 
murine model of inflammation-induced CRC.  Unlike the human cross-sectional studies, 
we demonstrated dynamic changes in the microbiome during the development of 
inflammation and tumorigenesis and that these changes directly cause disease. 
Based on this study, the gut microbiome complements the activity of AOM and 
DSS to cause tumorigenesis, but the underlying mechanisms driving microbial-mediated 
tumorigenesis observed remain to be elucidated.  Although a number of bacterial 
populations have altered relative abundances throughout the model, it is as yet unclear 
whether there is an increase in bacterial populations that induce inflammation or a loss 
of populations that produce anti-inflammatory signals and help maintain immune 
homeostasis in the gut.  Regardless, an increasingly inflammatory environment would 
generate a self-reinforcing pathogenic cascade between the gut microbiome and the 
host, fostering the development of cancer through the development of, for example, 
genotoxic reactive oxygen species and pro-tumor inflammatory mediators (e.g. TNF-a, 
IL-6, IL-1β, IL-23).  In addition to the role of the gut microbiome in inflammation, 
changes mediated by chronic inflammation and tumorigenesis could lead to the 
enrichment of bacterial populations [Couturier-Maillard et al., 2013] that have a direct 
role in tumor development through the production metabolites, antigens, virulence 
factors and other potential tumor-promoting gene products.  A recent study by Arthur et 
al. [Arthur et al., 2012] demonstrated that colonic inflammation in the IL-10-deficient 
mouse impacts the composition of the gut microbiome, leading to an enrichment of 
tumor-promoting E. coli strains.  Although we did not detect any significant changes in 
populations related to the genus Escherichia, it is likely that the microbial community 
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alterations we observed in our tumor model are enriched with populations that fill a 
similar role.  Specifically, marked increases in Bacteroides sp. in our study may 
contribute to tumorigenesis.  Human commensals belonging to the genus Bacteroides, 
specifically enterotoxigenic B. fragilis (ETBF), have been associated with inflammation 
and CRC [Wu et al., 2009; Sears et al., 2008].  ETBF has been shown to strongly 
induce colonic tumors in multiple intestinal neoplasia mice through secretion of a 
metalloprotease toxin and certain strains are thought to contribute to CRC risk in 
humans.  We did not detect ETBF in the murine gut microbiome (data not shown), but it 
is possible that similar processes are occurring during tumorigenesis in mice.   
Chronic inflammation and tumorigenesis are also likely to lead to the loss of members of 
the gut microbiome that are important for maintaining epithelial health and immune 
homeostasis.  In this study, we observed a dramatic decrease in OTUs from 
unclassified genera within the family Porphyromonadaceae.  We hypothesize that these 
bacterial populations serve a protective role and are important mediators of gut health in 
the murine gut microbiome.  One mechanism of protection could be through the 
fermentation of complex carbohydrates (e.g. fiber) into short chain fatty acids (SCFA) 
such as butyrate.  Butyrate reduces inflammation [Segain et al., 2000] and inhibits 
growth and induces apoptosis in cancer cells [Hague et al., 1995; Ruemmele et al., 
2003].  Therefore, loss of butyrate-producing populations in the gut could increase both 
inflammation and tumorigenesis. This is supported by extensive epidemiological data 
that demonstrates a link between diets high in fiber and decreased CRC risk [Aune et 
al., 2011].  Furthermore, recent studies have shown that both individuals who consume 
low fiber diets or are diagnosed with CRC have a lower level of SCFAs in their feces 
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[O’Keefe et al., 2009].   It is also possible that members of the family 
Porphyromonadaceae are important mediators of anti-inflammatory signals in the gut.  
A loss of such anti-inflammatory populations would lead to a dramatic intensification of 
inflammation in the gut during DSS induced colitis and a marked increase in tumor-
promoting signals. 
It is important to note that the gut microbiome is an extremely complex and 
diverse community and therefore, it is unlikely that a single bacterial population is 
responsible for driving tumorigenesis or that one CRC-associated microbiome can be 
found in all CRC patients.  Rather, as our data suggest, a community-wide effect 
involving the gain and loss of bacterial populations and general metabolic functions 
likely plays a critical role in CRC development.  As we demonstrated in this study, 
changes in the entire gut microbiome can dramatically alter tumor burden, and 
identifying the mechanisms behind this phenomenon will be critical for addressing how 








Figure 3.6. 16S rRNA quantitative qPCR. Relative fold decrease in 16S rRNA copy 
number during antibiotic treatment compared to baseline untreated samples.  All time 
points showed no significant decrease compared to baseline untreated samples (p = 














































Figure 3.7. Microbiome alterations associated with DSS induced inflammation.  A. 
Inverse Simpson’s diversity index.  B.  Average θYC distance between phase of the 










































































































Figure 3.8. Tumor size for antibiotic treated and germ-free mice. Measurement of 
the largest dimension of each tumor (mm) was performed using calipers for each mouse 
following AOM/DSS administration.  (A) Antibiotic-treated mice (n=10) versus 
conventional mice (n=12). P = 0.002.  (B) Gerfree mice colonized with a healthy 
community (n=10) versus a dysbiotic community (n=10).  P = 0.0019.  Statistical 
































































1 Bacteroides (genus) 3.99* 8.32 9.97 11.35 
3 Odoribacter (genus) 1.42 2.02 3.06 5.98* 
4 Prevotellaceae(family) 5.48* 3.07 2.67 3.18 
5 Prevotella (genus) 5.03 6.01 1.76* 2.44* 
6 Porphyromonadaceae (family) 4.99* 2.19 2.01 4.52 
7 Porphyromonadaceae (family) 4.15 3.06 2.61 2.6 
9 Bacteroidetes (phylum) 6.2 2.05* 4.09 1.71 
12 Porphyromonadaceae (family) 3.56 2.08 1.52 1.05 
13 Bacteroides (genus) 0.07 2.84 6.39 1.01 
14 Lactobacillus (genus) 0.98 1.69 2.2 2.89 
15 Porphyromonadaceae (family) 2.51 0.98 1.77 2.14 
18 Clostridiales (order) 1.39 1.78 0.58 0.82 
20 Turicibacter (genus) 0.16 1.57 1.69 1.54 
22 Porphyromonadaceae (family) 0.99 1.23 0.42 0.69* 
23 Alistipes (genus) 0.51 1.31 0.71 0.55* 
26 Erysipelotrichaceae (family) 0 0 0.69* 2.03* 
27 Anaeroplasma (genus) 1.51 2.31 0.21* 0.44* 
35 Clostridium (genus) 0* 0.8 1.06 1.39 
36 Bacteria (kingdom) 0 0.06 0.54 1.16* 
42 Lachnospiraceae (family) 0.71 0.91 0.08* 0.22 
48 Porphyromonadaceae (family) 1.58 0.36 0.14 0.36 
49 Bacteria (kingdom) 0.92 0.31 0.19 0.08 
51 Lactobacillus (genus) 0.72 0.47 0.5 0.22 
56 Porphyromonadaceae (family) 0.7 0.46 0.27 0.41 
59 Bacteroidales (order) 0.35 0.09 0.21 0.14 
62 Alphaproteobacteria (order) 0.42* 0.12 0.05 0.09 
66 Porphyromonadaceae (family) 0.67 0.49 0.17* 0.32 
69 Barnesiella (genus) 0.52* 0.12 0.41* 0.14 
70 Clostridiales (order) 0.39 0.72 0.24 0.08 
72 Porphyromonadaceae (family) 0.15 0.09 0.62* 0.28* 
81 Lachnospiraceae (family) 0.43 0.15 0.16 0.11 
85 Clostridium (genus) 0.02 0.16 0.48 0 
86 Bacteroidales (order) 0.65* 0.07 0.16 0.12 
87 Porphyromonadaceae (family) 0.31 0.25 0.13 0.12 
94 Porphyromonadaceae (family) 0.41 0.5 0.18 0.11* 
98 Bacteria (kingdom) 0.35* 0.12 0.07 0.09 
Table 3.1. Average relative abundance of significantly altered OTUs during 
AOM/DSS tumor induction.  OTUs included in table are significantly altered from 
baseline over time.  Significance was determined using repeated measure paired 
treatment analysis of variance and correcting for multiple comparisons using an 
experiment-wise error rate of 0.01.  Taxonomic group based on RDP classification is 




OTU # Taxonomy (level) Baseline DSS 
Round 3 
1 Bacteroides (genus) 1.2 7.75 
3 Odoribacter (genus) 1.87 11.23 
4 Prevotellaceae(family) 3.9 2.08 
6 Porphyromonadaceae (family) 1.66 0.45 
7 Porphyromonadaceae (family) 2.83 1.49 
9 Bacteroidetes (phylum) 0.16 2.53 
11 Erysipelotrichaceae (family) 3.7 0.2 
18 Clostridiales (order) 3.18 0.93 
20 Turicibacter (genus) 0 2.04 
21 Ruminococcus (genus) 2.46 0.21 
22 Porphyromonadaceae (family) 2.16 0.48 
26 Erysipelotrichaceae (family) 0 4.18 
28 Bacteroidales (order) 4.1 0.16 
30 Porphyromonadaceae (family) 2.97 1.42 
32 Akkermansia (genus) 1.05 0.2 
39 Odoribacter (genus) 0.75 1.83 
40 Clostridiaceae (family) 0.01 1.33 
41 Bacteroidetes (phylum) 0.32 5.65 
42 Lachnospiraceae (family) 3.33 0.11 
45 Porphyromonadaceae (family) 1.72 0.6 
47 Porphyromonadaceae (family) 0.51 0.1 
49 Bacteria (kingdom) 1.69 0.43 
53 Clostridiales (order) 0.46 0.1 
62 Alphaproteobacteria (class) 1.26 0.08 
67 Porphyromonadaceae (family) 0.07 0.57 
69 Barnesiella (genus) 0.57 0.13 
81 Lachnospiraceae (family) 0.5 0.07 
90 Bacteria (kingdom) 0.87 0.14 
96 Clostridiales (order) 0.86 0.05 
99 Lachnospiraceae (family) 0.97 0.15 
 
Table 3.2. Average relative abundance of OTUs for baseline and DSS round 3 in 
germ-free mice conventionalized with healthy microbiota. OTUs included in table 
are significantly altered from baseline over time in mice conventionalized with bedding 
from healthy mice.  Significance was determined using repeated measure paired 
treatment analysis of variance and correcting for multiple comparisons using an 
experiment-wise error rate of 0.01.  Taxonomic group based on RDP classification is 
represented for each OTU.   
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Materials & Methods 
Animals and animal care.  
Studies were conducted on adult (8 to 12 week old) age-matched male C57BL/6 
mice that were bred and maintained under SPF or germ-free conditions as specified 
above.  Mice were co-housed in groups of five.  Both SPF and germfree mice were fed 
the same autoclaved chow diet.  All animal experiments were approved by the 
University Committee on Use and Care of Animals at the University of Michigan. 
 
Inflammation-induced colon tumorigenesis.   
Eight to 12-week-old mice received a single intraperitoneal (i.p.) injection of 
azoxymethane (10 mg/kg).  Water containing 2% DSS was administered to mice 
beginning on day 5 for 5 days followed by 16 days of water.  This was repeated twice 
for a total of 3 rounds of DSS [Tanaka et al., 2003; Chen et al., 2008].  Mice were 
euthanized on days 14, 24, 38, and 45 for intermediate time point analysis.  The 
remaining mice were euthanized 3 weeks after the third round of DSS administration for 
tumor counting.  
 
Histological analysis.   
At necropsy, all colons were harvested, flushed of luminal contents, and cut open 
longitudinally to count and measure tumors.  The largest dimension of each tumor was 
measured with calipers.  Tumors were categorized based on size (<1mm, 1-2mm, 
>2mm).  Colons were then jellyrolled, fixed in Carnoy’s solution, and embedded in 
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paraffin.  Five-micrometer sections were used for H&E staining and slides were 
analyzed under 100X  magnification. 
 
RNA isolation and cytokine analysis.   
Distal colon tissue was homogenized and total RNA isolated using the 
Nucleospin RNA kit (Macherey-Nagel) cDNA was synthesized using iScript (Bio-Rad) 
and the cDNA was then used for quantitative qPCR using SYBR Green Expression 
Assay (Applied Biosystems).  
 
Antibiotic treatment.   
Mice were treated with an antibiotic cocktail of metronidazole (0.75 g/L), 
vancomycin (0.5 g/L), and streptomycin (2 g/L) in their drinking water for 2 weeks prior 
to and throughout the duration of AOM/DSS administration.  
 
Germ-free colonization.   
Eight-week-old C57BL/6 germ-free male mice were used.  Fresh feces and 
bedding were collected from untreated and AOM/DSS-treated tumor-bearing mice and 
immediately transferred to cages of germ-free mice two weeks prior to AOM injection to 
allow stable colonization.  Germfree mice were divided into two treatment groups, one 
group receiving bedding from untreated, healthy, the other group receiving bedding from 
AOM/DSS-treated tumor-bearing mice.  To ensure that there were no cage effects, 
each treatment group was comprised of two cages of mice.  The mice were obtained 
from separate litters and randomly assigned to the four cages.  Mice were given three 
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weeks following colonization with feces and then treated with AOM/DSS to induce 
tumors as described above.  Three weeks after the last round of DSS, mice were 
euthanized and colons were harvested as described above. 
 
DNA extraction.   
Fecal samples were collected daily from the mice throughout the AOM/DSS 
protocol and immediately frozen for storage at -20°C.  We selected 12 fecal samples 
distributed over the 73-day timeline of the AOM/DSS model for 10 representative mice 
taken from five replicate cages. Microbial genomic DNA was extracted using the 
PowerSoil-htp 96 Well Soil DNA Isolation Kit (MO BIO laboratories) using an EpMotion 
5075. 
 
16S rRNA gene sequencing and curation.   
The V35 region of the 16S rRNA gene from each sample was amplified and 
sequenced using the 454 Titanium sequencing platform at the Baylor College of 
Medicine Human Genome Sequencing Center as described elsewhere 
(http://www.mothur.org/wiki/454_SOP).  We curated our sequences as described 
previously using the mothur software package [Schloss et al., 2012; Schloss et al., 
2009; Schloss et al., 2011].  Briefly, we denoised sequences using the PyroNoise 
algorithm after trimming each flowgram to 450 flows [Quince et al., 2009], aligned the 
resulting sequences to a reference alignment derived from the SILVA 16S rRNA 
sequence database [Pruesse et al., 2007], and removed sequences that were flagged 
as possible chimeras by UCHIME [Edgar et al., 2011] or that did not align to the V35 
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region.  After curating the sequence data, we obtained between 6 and 10,742 
sequences (median = 5681) with a median length of 253 bp.  To minimize biased effects 
of uneven sampling, we rarefied to 1,800 sequences per sample.  Seven samples either 
did not pass through sequence curation or had less than 1,800 sequences and were 
therefore not used for further analysis.  Parallel sequencing of a mock community 
allowed us to measure a median error rate of 0.06%. 
 
Analysis of the microbiome.   
Sequences were clustered into OTUs based on a 3% distance cutoff using the 
average neighbor algorithm.  All sequences were classified using the RDP training set 
version 9 (http://sourceforge.net/projects/rdp-classifier/) and OTUs were assigned a 
classification based on which taxonomy had the majority consensus of sequences 
within a given OTU using a naïve Bayesian classifier [Wang et al., 2007].  Microbial 
diversity was calculated using inverse Simpson index [Magurran, 1988] and the 
observed number of OTUs.   To calculate β-diversity, we used the θYC distance metric 
with OTU frequency data [Yue et al., 2005] and we calculated UniFrac statistics 
[Lozupone et al., 2005] using neighbor joining phylogenetic trees generated using the 
non-heuristic neighbor joining algorithm implemented in Clearcut [Shenaman et al., 
2006].  Analysis of molecular variance (AMOVA) was performed to determine 
significance between the community structures of different groups of samples based on 
θYC and UniFrac distance matrices [Martin, 2002].  To identify OTUs important for 
driving differences between groups (baseline, after DSS round 1, after DSS round 2, 
and after DSS round 3), we used a repeated measure paired treatment analysis of 
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variance for each OTU and corrected for multiple comparisons using an experiment-
wise error rate of 0.01 [Benjamini et al., 1995].  Additionally, we identified features 
(OTUs) important for each group using the machine learning algorithm random forest as 
implemented in R (http://CRAN.R-project.org) [Liaw et al., 2002].  The abundance-
based Jaccard dissimilarity index indicates the fraction of all sequences that affiliate 
with OTUs that are shared between two communities and was used to calculate the 
fraction of OTUs that were shared between donor samples and germ-free recipient 
samples [Chao et al., 2006].  All sff files and the MIMARKS spreadsheet are available at 
http://www.mothur.org/aomdss_dynamics/. 
 
16S rRNA quantitative PCR (qPCR) analysis.   
Relative bacterial loads in stool samples were quantified by qPCR analysis of 
bacterial genomic DNA using KAPA SYBR-fast Master Mix (KAPA biosciences) and 
universal 16S rRNA gene primers (F: ACTCCTACGGGAGGCAGCAGT. R: 
ATTACCGCGGCTGCTGGC.) [Vaishnava et al., 2011].  Samples were normalized to 
fecal mass and relative fold change was determined using untreated stool samples for 
each replicate mouse (n=5).  Note that qPCR measures relative fold change of 16S 
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Manipulation of the Gut Microbiome Reveals Role for Microbial Community 




The mammalian gastrointestinal tract is home to a complex and dynamic 
community of microorganisms, termed the gut microbiome, which is essential for the 
health of the host [Backhed et al., 2005].  Over the last several years it has been well 
document that abnormalities in this community are associated with colorectal cancer in 
humans and mice [Chen et al., 2013; Chen, et al., 2012; Kostic et al., 2012; Geng et al., 
2013; Shen et al., 2013; Sobhani et al., 2011; Wang et al., 2012; Ahn et al., 2013].  We 
have previously demonstrated that in a mouse model, CRC-associated changes in the 
gut microbiome directly potentiate colon tumorigenesis [Zackular et al., 2013].  A critical 
question that remains unanswered is what factors and ecological principles mediate the 
gut microbiome’s influence on this process [Fearon, 2011].   
One strategy that has been used to answer this question is through the 
examination of individual bacteria populations within the gut microbiome.  It has been 
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demonstrated that several common commensal bacteria have the capability to directly 
influence the process of tumor development and progression in the colon.  The 
mechanisms by which bacteria potentiate these processes range from the production of 
carcinogenic toxins [Arthur et al., 2012; Sears et al., 2008] to direct manipulation of the 
inflammatory status in a tumors microenvironment [Kostic et al., 2013; Rubinstein et al., 
2014].  Furthermore, some bacterial populations have been hypothesized be protective 
against CRC [Louis and Flint, 2009; Arthur et al., 2011; Appleyard et al., 2011].  This 
may be mediated through metabolite production, induction of immunotolerance, or an 
ability to outcompete pathogenic bacteria  [Zhu et al., 2011].  
Although there have been several associations between members of the gut 
microbiome and colorectal cancer, there is likely to be many bacteria that can modulate 
tumorigenesis in the colon.  This is supported by studies that have identified 
abnormalities in the microbial communities associated with CRC in humans [Chen et al., 
2013; Chen, et al., 2012; Kostic et al., 2012; Geng et al., 2013; Shen et al., 2013; 
Sobhani et al., 2011; Wang et al., 2012; Ahn et al., 2013].  Each of these studies 
reported abnormal shifts in the gut microbiome, termed dysbiosis; however, there were 
no CRC-associated bacterial populations that were consistently identified across all 
studies.  This could be due to the fact that there is significant functional redundancy 
within the gut microbiome and different bacterial populations may fill similar roles in 
tumorigenesis [Lepage et al., 2011; Turnbaugh et al., 2009; Qin et al., 2010].  We 
hypothesize that multiple bacteria in the gut microbiome have the potential to play 
antagonistic or protective roles in tumorigenesis; thus, the gut microbiome’s influence 
on CRC is likely polymicrobial.  
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Within host-associated microbial communities there are complex interactions 
between individual bacterial populations that have an important effect on host health 
[Levy and Bordenstein, 2013, Marino et al., 2013, Lepp et al., 2004].  The number of 
diseases that are associated with abnormalities in the gut microbiome highlights the 
importance of these ecological interactions [Turnbaugh et al. 2006; Tamboli et al.; 2004, 
Saulnier et al., 2011].  Deciphering how changes in community composition and 
structure disturb these interactions, and subsequently modulate tumorigenesis, is an 
essential step in understanding the etiology of CRC.  In our previous study, treatment 
with antibiotics dramatically decreased tumorigenesis without a significant decrease in 
overall bacterial burden in the colon.  Our results suggest that microbial community 
structure may play an important role in both down modulating and enhancing 
tumorigenesis.  However, it remains unclear if manipulation of the community structure 
directly determines the carcinogenicity of the gut microbiome. 
Previously, we found that when mice received metronidazole, streptomycin, and 
vancomycin in their drinking water and were then treated to induce inflammation-
associated CRC, there was a significant decrease in tumorigenesis [Zackular et al, 
2013].  Here we explored this result further by altering the composition of this antibiotic 
cocktail to test the hypothesis that the gut microbiome structure mediates tumor 
multiplicity and severity.  Furthermore, we sequenced the V4 region of the 16S rRNA 
gene from treated mice in each group and determined that each treatment generated 
non-overlapping microbial community structures with varying levels of carcinogenicity.  
Using antibiotics to intervene following the first signs of dysbiosis, we demonstrated the 
feasibility of targeting the gut microbiome as a therapeutic for CRC.  Our analysis 
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supports a model by which individual bacterial populations play an important role in 
CRC, but the ecological interactions and community structure of the gut microbiome 
mediate the capacity to modulate tumorigenesis. 
 
Results 
Antibiotic perturbation of the gut microbiome modulates tumorigenicity. 
To test the hypothesis that gut microbiome structure mediates tumorigenesis, we 
administered an assortment of antibiotic treatments to specific-pathogen-free (SPF) 
C57BL/6 mice and treated them with the azoxymethane (AOM) and DSS inflammation-
based model of CRC [Zackular et al., 2013] (Figure 4.1A).  We treated mice with all 
possible combinations of metronidazole, streptomycin, and vancomycin to create eight 
treatment groups: no antibiotics, all antibiotics (metronidazole, streptomycin, and 
vancomycin), Δmetronidazole (streptomycin and vancomycin), Δstreptomycin 
(metronidazole and vancomycin), Δvancomycin (metronidazole and streptomycin), 
metronidazole only, streptomycin only, and vancomycin only.  Each treatment group 
showed a significant decrease in tumor multiplicity compared to mice that did not 
receive antibiotics; however, all of the antibiotic treatments resulted in varying levels of 
tumorigenesis (Figure 4.1A). These results demonstrate that distinctive antibiotic 






Figure 4.1.  Antibiotic perturbation of the gut microbiome modulates 
tumorigenicity. A. Mice were injected with azoxymethane (AOM) on day 1 followed by 
3 subsequent rounds of water administered 2% DSS.  Colons were harvested 73 days 
after AOM and tumors grossly counted.  Black wedges indicate fecal samples used for 
gut microbiome analysis.  Antibiotic perturbation was started 2 week prior to AOM 
injection and continued throughout the model.  B.  Mice were treated with all possible 
combinations of metronidazole, streptomycin, and vancomycin to create eight treatment 
groups.  Tumors were enumerated at the end of the model.  C. Representative images 
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Marked structural changes associated with each antibiotic treatment could be 
observed at the phylum level (Figure 4.2C). Untreated control mice were are dominated 
by the phlya Bacteroidetes (65±5.7%), Firmicutes (24±4.6%), and Proteobacteria 
(3±1.1%) (Figure 4.2A).  The mice that received the full antibiotic cocktail primarily 
harbored Firmicutes (92±3%), particularly from the family Lactobacillaceae.  In contrast, 
the mice that received only metronidazole had similar levels of Bacteroidetes (74±4%) 
and Firmicutes (7±1%) as control mice, but there was a significant bloom in 
Proteobacteria (9±0.08%).   The Δmetronidazole and Δstreptomycin treatments led to 
the dominance of Proteobacteria (66±5% and 75±5%, respectively). The Δvancomycin 
treated mice harbored Firmicutes (48±8%) and Proteobacteria (48±12%).  The mice that 
received only vancomycin were composed of bacterial populations belonging to the 
phyla Firmicutes (12±3%), Proteobacteria (38±2%), Tenericutes (18±6%), and 
Verrucomicrobia (27±12%).  These results demonstrate that antibiotic treatments 
perturbed the structure of the microbial community, leading to 7 distinct communities 
that were associated with varying levels of tumorigenesis.  
To examine the role of the microbial community in this variation in tumorigenesis, 
we first considered the diversity of the gut microbiome using fecal samples taken at the 
end the model (Figure 4.1A).  Each antibiotic treatment resulted in a significant 
decrease in the microbial diversity compared to mice that did not receive antibiotics.  
Mice treated with streptomycin or metronidazole alone showed intermediate levels of 
diversity that were significantly higher than the remaining treatments (Figure 4.2A).  
However, there was no direct correlation between changes in diversity and 
tumorigenicity of the microbial community.  To determine if there was an association 
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with a decrease in bacterial burden in the colon and tumorigenesis, we next looked at 
overall bacterial numbers in the feces.  Using qPCR of the 16S rRNA gene we 
determined that there was not a significant decrease in overall bacterial numbers 
following treatment.  These results indicate that the mere bacterial load or diversity of 
the community was insufficient to explain the differences in tumor burden. 
Next, we characterized the differences in the structures of the communities by 
calculating the distance between samples using a metric that incorporates the OTU 
membership and relative abundance (i.e. θYC) [Yue and Clayton, 2005].  Each antibiotic 
treatment group harbored a significantly altered microbiome at the end point of the 
model compared to untreated animals (Figure 4.2B).   Furthermore, each treatment 
resulted in a significantly different community structure, as each treatment group 
clustered separately from one another (Figure 4.2B).  Similar results were observed 
when we used phylogenetic-based metrics of β-diversity (i.e. θYC and weighted and 
unweighted UniFrac).  These results indicate that highly disparate community structures 





Figure 4.2.  Antibiotic perturbation drives changes in microbial community 
structure.  Microbiome analysis was performed on fecal samples from each mouse on 
days indicated in Figure 1A.  A. Inverse Simpson’s diversity index of fecal samples 
taken at the endpoint of the model. B. NMDS ordination based on θyc distances for all 
mice following the third DSS administration.  (AMOVA; P < 0.01; Stress = 0.175). C.  
Phylum level relative abundance for each treatment group.  Relative abundance 































































































Identification of tumor modulating bacterial populations in the gut microbiome 
The clear differences in community structure and composition coupled with the 
disparate levels of tumorigenesis provided us with an opportunity to identify potentially 
protective or tumor-promoting bacterial populations.  To identify these tumor-modulating 
OTUs, we partitioned the treatment groups into high tumor incidence (Δmetronidazole, 
streptomycin only, and vancomycin only; median number of tumors=5.5) and low tumor 
incidence (All antibiotics and Δvancomycin, Δstreptomycin and metronidazole only 
median number of tumors=2.0).  We then used LEfSe to identify differentially abundant 
bacterial populations that were associated with an increased or decreased tumor 
burden in mice (Figure 4.3).  We observed that four OTUs were significantly enriched 
among treatment groups with a higher tumor burden (Figure 4.3).  Among the mice in 
the treatments with a low tumor burden there were 12 OTUs that were significantly 
enriched (Figure 4.3).  Using Spearman correlation analysis we confirmed that these 
bacterial populations were highly correlated with an increased or decreased tumor 
burden in mice.  These results indicate that there are populations that are associated 
with promoting or protecting against tumorigenesis. 
Interestingly, when we investigated the relative abundance of these OTUs for 
each treatment group, we observed that the distribution of these OTUs was patchy 
across the treatment groups (Figure 4.4).  For example, among the three groups with 
the most tumors, β-Proteobacteria (OTU 25) was highly abundant among the 
Δmetronidazole group, significantly less abundant in vancomycin only group, and 
completely absent from the streptomycin only group.  In contrast, Mucinispirillum (OTU 
87) was absent in the Δmetronidazole group, but elevated in the other two treatment 
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groups.  This result suggests that there was not a single bacterial population promoting 
tumorigenesis in mice.  Instead it is likely that there are populations of tumor promoting 
bacteria and tumor suppressing bacteria that can interact or serve redundant roles to 
modulate tumor burden. 
 
Microbiome dynamics reveal potential associations between bacterial 
populations that mediate tumorigenesis 
Comparison of the communities in the initial and final fecal samples collected 
from each treatment group indicated that the groups varied in the amount of change 
over the course of the model.  The mice that received streptomycin or vancomycin only 
and the Δstreptomycin mice had significantly less structural change overtime compared 
to control mice (Fig. 4.4A).  Meanwhile, the mice that received the full cocktail 
maintained a constant community structure throughout the model.  Conversely, the 
Δmetronidazole and Δvancomycin mice had the highest level of variation across the 
model (Figure 4.4A).  The amount that the gut microbiome changed was not directly 
correlated with tumor burden (rho = 0.15, p = 0.41).  This result indicated that the 
destabilization of the initial community structure and the resulting host response was not 





Figure 4.3.  Analysis of bacterial populations associated with increased and 
decreased tumorigenesis.  Antibiotic treatment groups were partitioned into two 
groups based on tumor burden: high tumor burden (∆metronidazole, vancomycin only, 
and streptomycin only) and low tumor burden (All antibiotics, ∆streptomycin, 
∆vancomycin, and metronidazole).   LEfSe analysis was performed for stool samples 
from each mouse at the endpoint of the model. Strip charts show relative abundance for 
































































































































Figure 4.4. Relative abundance of significantly enriched OTUs for each treatment 
group.  Strip charts show relative abundance of OTUs identified with LEfSe analysis for 
each treatment group separately.  Abundance data is taken from endpoint of the model 
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We determined whether the OTU-level changes across the model could reveal 
underlying mechanisms associated with this dramatic difference in tumorigenicity 
between treatment groups.  Thus, we performed repeated-measures paired group 
analysis of variance to identify features from within the microbiome that were 
significantly enriched or depleted overtime for each treatment group.  We used fecal 
samples from day 0 and compared those to samples at the endpoint of the model for 
the Δmetronidazole and Δvancomycin treated groups since these communities showed 
the greatest change over the course of the model (Figure 4.5A).  In both groups there 
was a significant enrichment of an OTU associated with the Enterobacteriaceae (OTU 
3) family.  In the Δmetronidazole-treated mice, this enrichment was associated with the 
simultaneous depletion in the relative abundance of Clostridium (OTUs 31, 34, and 57), 
Streptococcus (OTU 92), and Enterococcus (OTU 27).  However, Δvancomycin-treated 
mice only showed a significant decrease in OTUs associated with Lactobacillus (OTU 
6), while maintaining steady levels in each of the depleted populations observed in 
∆metronidazole treated mice.  We also observed enrichment in the relative abundance 
of Turicibacter (OTU 91) and Bacillales (OTU 225) in ∆vancomycin treated mice.  These 
results support the hypothesis that the balance of tumor promoting and inhibiting 





Figure 4.5.  Gut microbiome dynamics during tumorigenesis for Δmetronidazole 
and Δvancomycin treatments groups.   A.  Average change in the gut microbiome 
community structure over the time course of tumorigenesis.  Distances calculated using 
θyc distances.  B. and C.  Change in relative abundance over the time course of 
tumorigenesis for Δmetronidazole and Δvancomycin treatment groups.  OTUs with 
relative abundances that were significantly different at day 70 compared to day 0 are 
shown.  Repeated-measures paired group analysis of variance was used to identify 






















































































































































































































































































































































































































Antibiotic intervention narrows possible mechanisms of microbiome involvement 
in tumorigenesis  
The AOM-DSS model closely mirrors the patterns seen in human CRC.  AOM 
induces DNA damage and the DSS induces inflammation.  To determine whether the 
gut microbiome facilitates tumorigenesis by modulating AOM-induced mutations or 
inflammation, we performed two antibiotic intervention experiments.  We first treated 
mice with the full antibiotic cocktail two weeks prior to the administration of AOM and up 
until the first round of DSS (Figure 4.1A).  We found that these mice had a similar tumor 
burden to untreated mice (Figure 4.6A).  Next, we treated mice before the second round 
of DSS administration with the all antibiotic cocktail (Figure 4.1A).  In this treatment, 
there was a significant decrease in the number of tumors.  Together, these results 
suggest that the gut microbiome’s affect on CRC is independent of AOM 
carcinogenesis.  Furthermore, it shows that targeting the gut microbiome at later stages 
of tumor growth is a viable option for minimizing tumorigenesis and highlights 





Figure 4.6.  Antibiotic intervention prior to second administration of DSS 
alleviates tumor burden.  Interventions with an antibiotic cocktail of metronidazole, 
vancomycin, and streptomycin were performed as depicted in Figure 1A.  A.  Tumors 
were enumerated at the end point of the model.  Median tumor counts are shown for 
each treatment group.  B.  Representative images of tumors in the distal colon of mice 
from each treatment group.  Statistical analysis was performed using Wilcoxon test.  *, 
P < 0.01 
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In the present study, we established the importance of the microbial community 
structure in mediating the gut microbiome’s capacity for tumorigenesis.  We 
demonstrated that manipulation of the murine gut microbiome with an assortment of 
antibiotic treatments resulted in non-overlapping community structures with a disparate 
level of tumorigenesis.  Enrichment in the relative abundance of several bacterial 
populations was associated with high and low levels of colonic tumors.  We determined 
that out growth of potentially inflammatory members of the gut microbiome only 
mediated increased tumorigenesis when there was a corresponding decrease in 
potentially protective, butyrate producing, bacteria.  By perturbing the community at 
various time points in the AOM/DSS model, we determined that the gut microbiome is 
likely potentiating tumorigenesis independent of AOM-carcinogenesis.  Our experiments 
also demonstrated that targeting the gut microbiome at the first signs of dysbiosis is a 
viable strategy for the amelioration of colon tumorigenesis. 
In recent years, there has been a focus on identifying bacterial populations that 
are etiologic agents of CRC.  Several commensal bacteria, including Fusobacterium 
nucleatum and enterotoxigenic Bacteroides fragilis (ETBF) have been linked to CRC in 
humans [Arthur et al., 2013; Rubinstein et al.; 2013, Sears et al., 2008].  F. nucleatum 
can manipulate the inflammatory environment on in the tumor microenvironment in 
multiple intestinal neoplasia mice and in the studied population has been detected on 
the surface of over 50% of adenomas [Kostic et al., 2012; Kostic et al., 2013].  ETBF 
increases tumor multiplicity in the colon of multiple intestinal neoplasia mice through the 
action of a secreted metalloprotease toxin.  It has been estimated that between 5-35% 
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of people carry ETBF [Housseau and Sears, 2010].  Although there is substantial 
evidence for a role in potentiating tumorigenesis, the fact that each of these bacteria is 
only associated with a fraction of CRCs suggests that there isn’t likely one microbial 
agent that causes cancer.  Rather, the gut microbiome’s role in CRC is likely 
polymicrobial.  The results in the present study support this hypothesis, as we 
demonstrated that non-overlapping community structures could confer similar levels of 
tumorigenesis in mice.  When we examined the relative abundance of bacterial 
populations associated with increased tumor burden, we never observed all three 
treatment groups with high tumor levels (vancomycin only, streptomycin only, and 
∆metronidazole) showing a consistent enrichment.  The same was observed with 
potentially protective populations across all treatment groups that developed 
significantly less tumors (All antibiotics, ∆vancomycin, ∆streptomycin, and 
metronidazole only).  This suggests that various bacteria within the gut microbiome may 
confer the same function and be playing redundant tumor-modulating roles. 
During the time course of tumorigenesis we observed a marked increase in 
members of the Enterobacteriaceae associated with two antibiotic treatment groups 
(∆metranidazole and ∆vancomycin).  Interestingly, one treatment group (∆vancomycin) 
developed significantly less tumors despite a similar increase in this potentially tumor-
modulating bacterial clade.  A recent study by Arthur and colleagues showed that in an 
IL-10-deficient colitis-associated mouse model of CRC; there is an enrichment of 
Enterobacteriaceae associated with inflammation [Arthur et al., 2012].  This leads to an 
expansion of E. coli strains with genotoxic capabilities and a consequential increase in 
tumor multiplicity and invasion.  Furthermore, members of the Enterobacteriaceae have 
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been shown to perpetuate inflammation in several inflammatory diseases, including 
ulcerative colitis, which increase an individual’s risk of developing CRC [Rolhion and 
Darfeuille-Michaud, 2007; Garrett et al., 2007; Rooks et al., 2014].  When we further 
examined the two antibiotic treatment groups, we observed that mice with an increased 
tumor burden had a corresponding decrease in several potentially anti-inflammatory and 
butyrate producing bacterial populations.  These observations support a model by which 
the pathogenicity of individual members of the gut microbiome is mediated by the 
community structure and ecological interactions within the gut microbiome.  We 
hypothesize that inflammatory and carcinogenic commensal bacteria, such as 
Enterobacteriaceae, can only mediate a pathogenic phenotype if the context of the 
community structure is conducive. 
One mechanism by which community structure likely mediates tumorigenicity is 
through shifts in the balance of immunomodulatory metabolites and signals.  During 
health, the gut microbiome is an important mediator of immunotolerance, but when the 
balance of pro- and anti-inflammatory signals is disrupted gut pathologies can arise 
[Kelly et al., 2005].  In our mice, Enterobacteriaceae is likely acting as an inflammatory 
member of the gut microbiome.  We only observed an increase in tumorigenesis when 
there was a corresponding depletion of potentially protective members of the genera 
Clostridium, Enterococcus, and Streptococcus.  Members of the Clostridium are known 
producers of short chain fatty acids (SCFA) in the colon [Louis et al., 2009].  SCFA, 
specifically butyrate, are important nutrients for colonocytes and they also possess anti-
inflammatory and anti-tumor properties [Louis et al., 2009].  Furthermore, Enterococcus 
and Streptococcus species have been linked to down-regulating the inflammatory 
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response in the colon [Wang et al., 2008; Kaci et al, 2011].  It is likely that these 
bacterial populations have the ability to antagonize inflammatory clades (e.g. 
Enterobacteriaceae) and confer protection; however, when perturbation to the microbial 
community structure disrupts this homeostasis, these opportunistic pathogens can 
potentiate tumorigenesis 
In our previous work, we demonstrated that dysbiosis of the gut microbiome 
generates a pro-inflammatory environment which results in a self-reinforcing pathogenic 
cascade between the gut microbiome and the host [Zackular et al., 2013].  In this study 
we demonstrated that antibiotic manipulation of the gut microbiome after the initiation of 
inflammation and tumorigenesis can significantly decreased tumorigenesis in mice.  
This highlights the efficacy of targeting the gut microbiome in CRC.  Additional studies 
are needed to explore the viability of manipulating the gut microbiome in CRC with 





Materials & Methods 
Animals and animal care.  
Studies were conducted using adult (8 to 12 week old) age-matched C57BL/6 
male mice that were maintained under SPF conditions.  Mice were co-housed in groups 
of five and fed the same autoclaved chow diet.  All animal experiments were approved 
by the University Committee on Use and Care of Animals at the University of Michigan. 
 
Inflammation-induced colon tumorigenesis.   
Mice received a single intraperitoneal (i.p.) injection of azoxymethane (10 mg/kg).  
Water containing 2% DSS was administered to mice beginning on day 5 for 5 days 
followed by 16 days of water.  This was repeated twice for a total of 3 rounds of DSS 
[Zackular et al., 2013].  Mice were euthanized 3 weeks after the third round of DSS 
administration for tumor counting.  At necropsy, all colons were harvested, flushed of 
luminal contents, and cut open longitudinally to count and measure tumors.   
 
Antibiotic treatment.   
Mice were treated with all possible combinations of metronidazole (0.75 g/L), 
streptomycin (2 g/L), and vancomycin (0.5 g/L) to create eight treatment groups: no 
antibiotics, all antibiotics (n=5) (metronidazole, streptomycin, and vancomycin), 
Δmetronidazole (n=5) (streptomycin and vancomycin), Δstreptomycin (n=5) 
(metronidazole and vancomycin), Δvancomycin (n=5) (metronidazole and streptomycin), 
metronidazole only, streptomycin only, and vancomycin only (n=3).  Antibiotics were 
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administered in mouse drinking water for 2 weeks prior to and throughout the duration 
of AOM/DSS administration, unless otherwise specified in Figure 4.1A.  Tumors were 
enumerated at the end of the model.  
 
DNA extraction and 16S rRNA gene sequencing 
Fecal samples were collected daily from the mice throughout the AOM/DSS 
protocol and immediately frozen for storage at -20°C.  For each mouse, 8 fecal samples 
distributed over the 73-day timeline of the AOM/DSS model were selected for analysis 
(Figure 4.1A). Microbial genomic DNA was extracted using the PowerSoil-htp 96 Well 
Soil DNA Isolation Kit (MO BIO laboratories) using an EpMotion 5075.  The V4 region of 
the 16S rRNA gene from each sample was amplified and sequenced using the Illumina 
MiSeq Personal Sequencing platform as described elsewhere [Kozich et al., 2013].  
Sequences were curated as described previously using the mothur software package 
[Schloss et al., 2009].  Briefly, we reduced sequencing and PCR errors, aligned the 
resulting sequences to the SILVA 16S rRNA sequence database [Pruesse et al., 2007], 
and removed any chimeric sequences flagged by UCHIME [Edgar, 2011].  Sequences 
had a median length of 253 bp and we rareified to 2,500 sequences per sample to limit 
effects of uneven sampling. 
 
16S rRNA quantitative PCR (qPCR) analysis.   
Relative bacterial loads were quantified by qPCR analysis of bacterial genomic 
DNA using KAPA SYBR-fast Master Mix (KAPA biosciences) and universal 16S rRNA 
gene primers (F: ACTCCTACGGGAGGCAGCAGT. R: ATTACCGCGGCTGCTGGC.) 
	  
 120	  
[Vaishnava et al., 2011].  Samples were normalized to fecal mass and relative fold 
change was determined using untreated stool samples for each replicate mouse.  Note 
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CRC is one of the most commonly diagnosed malignancies worldwide, affecting 
millions of people each year.  Significant risk factors for CRC such as fatty diets, 
physical inactivity, and chronic inflammation have been associated with altered 
composition, metabolism, and function of the resident gut microbiome.  Furthermore, 
various physiological functions that are associated with cancer, including cell 
proliferation, angiogenesis, and apoptosis, are modulated by the gut microbiome. 
Recent survey based studies have reported an association between dysbiosis of the gut 
microbiome and CRC [Chen et al., 2013; Chen et al., 2012; Kostic et al., 2012; Geng et 
al., 2013; Shen et al., 2013; Sobhani et al., 2011; Wang et al., 2012; Ahn et al., 2013].  
However, these studies have not explored the potential of using the gut microbiome as 
a biomarker for CRC.  Furthermore, it remains unclear if dysbiosis of the gut 
microbiome directly modulates tumorigenesis in the colon or if they are just a 
consequence of physiological changes in the tumor microenvironment.  The research 
presented in this dissertation revealed the potential of the gut microbiome as a non-
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invasive biomarker for CRC development.  In addition, we determined that dysbiosis 
has a causal role in the development of CRC and we further uncovered the factors 
important for gut microbiome mediated modulation of tumorigenesis.  In this chapter, I 
will discuss the overall impact of the findings in this dissertation and elucidate the 
potential mechanisms by which the gut microbiome modulates CRC.  I will then provide 
a proposed model and discuss the future directions of this research.  
 
Dysbiosis of the Gut Microbiome is Predictive of CRC 
 Early detection of CRC is essential for the long-term prognosis of patients.  
Currently, it is estimated that over 30% of adults do not receive risk appropriate 
screenings and over 50% of people prefer non-invasive screening methods [Benson et 
al., 2007; Leard et al., 1997; Ling et al., 2001].  This highlights a clear need for the 
development of novel non-invasive screening methods for the detection of CRC.  It is 
well established that dysbiosis of the gut microbiome is associated with CRC patients, 
but the viability of using the gut microbiome as a potential screen remains unexplored. 
In chapter II, to test the hypothesis that the gut microbiome can be used as a biomarker 
for the early detection of CRC, we acquired stool samples from the early detection 
research network (EDRN), an initiative created to discover biomarkers for cancer.  The 
EDRN has a wealth of stool samples and clinical metadata from patients who have 
been diagnosed with various stages of CRC. In our study, we selected samples from 
patients that were diagnosed with adenomas, carcinomas, and healthy controls.  A 
benefit to this design was that it allowed us to analyze changes in the gut microbiome 
that were associated with each step in the multistage progression of CRC (Figure 1.1).  
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Using microbial biomarker discovery algorithms [Segata et al., 2011], we were able to 
identify several bacterial populations that were differentially abundant between each 
clinical group.  Using the relative abundances of these bacteria, we generated logit 
regression models using both clinical and microbiome data for each subject.  We 
included microbial biomarkers that were both enriched and depleted for each 
comparison.  This is important because we believe that in addition to increases in 
populations, depletion of members of the gut microbiome are equally as important for 
the biology and detection of CRC.  For each comparison we made, we observed a 
significant improvement in our ability to predict the presence of adenomas and 
carcinomas upon inclusion of the microbiome data.  Furthermore, we determined that 
using gut microbiome data as a screening tool improved the pre-test to post-test 
probability of adenoma over 50-fold.  These findings demonstrated, for the first time, 
that the gut microbiome has the capability to serve as an accurate screening tool for 
early detection of CRC.  Our results strongly suggest that consideration must be given 
to the gut microbiome in concert with clinical data and existing non-invasive diagnostics 
to yield the most accurate diagnosis of CRC.   
 
The Dynamics of Dysbiosis 
 Based on the data from this dissertation and studies performed by several other 
groups, it was clear that shifts in the gut microbiome are associated with CRC.  
However, it still remained unclear whether these changes were driving tumorigenesis or 
if they were just a consequence of this disease.  We could not easily test this in 
humans, so in chapter III, we investigated the role of gut microbiome dysbiosis in a 
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mouse model of CRC.  We used a well characterized model of inflammation associated 
CRC and examined the dynamics of the gut microbiome during tumorigenesis.  Similar 
to what has been observed in humans with CRC, tumor-bearing mice harbored a 
dramatically altered microbial community.  A major caveat to our study in chapter II was 
that we only surveyed each community at one time point.  This cross-sectional design 
did not allow us to assess the changes in a CRC-associated microbiome over the time 
course of CRC development.  We hypothesized that the dynamics of the gut 
microbiome during tumorigenesis would reveal the underlying mechanisms driving the 
development and progression of dysbiosis.  To test this, we sampled each mouse daily, 
which enabled us to see the changes in the microbiome during tumorigenesis.  Results 
from this longitudinal study revealed that there was a stepwise progression in the gut 
microbiome, which ultimately led to what we classified as a tumor-associated dysbiosis.  
We also determined that DSS-induced inflammation alone did not lead to the 
development of tumors and was insufficient for the development of a tumor-associated 
dysbiosis.  In order to develop a tumor-associated dysbiosis, AOM and DSS were both 
needed.  This is important because Arthur and colleagues have suggested that 
inflammation alone is sufficient to generate a tumor-associated dysbiosis [Arthur et al., 
2012].  Our results support a model by which the synergistic effects of inflammation and 
tumorigenesis are necessary for the development of an altered microbiome structure 
and tumorigenesis.  We believe that the physiological changes that occur in the mucosa 
during inflammation and tumor development contribute collectively to dysbiosis. 
 
The Gut Microbiome Modulates Colon Tumorigenesis 
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Dysbiosis of the gut microbiome has been associated with many diseases, including 
obesity, inflammatory bowel disease, and CRC [Turnbaugh et al., 2006; Tamboli et al., 
2004].  Although correlations have been observed between dysbiosis and disease, it is 
unclear if a dysbiotic microbiome induces disease progression, e.g. tumorigenesis.  In 
chapter III, I tested the hypothesis that tumor-associated changes to the gut microbiome 
directly contribute to tumorigenesis.  Germ-free mice were inoculated with microbiota 
from healthy and tumor-bearing mice and were run through the AOM/DSS model.  Mice 
that received a dysbiotic gut microbiome developed significantly more tumors than 
those receiving a healthy microbiota.  For the first time, we revealed a direct causative 
role of tumor-associated changes in the gut microbiome in the development of CRC.  
This new information indicated that the interactions between inflammation, the tumor 
microenvironment, and subsequent changes in the gut microbiome create the 
conditions that result in colon tumors. 
 Studies previous to the work presented in my thesis have focused on the role of 
individual bacterial pathogens on tumor development.  These types of studies largely 
ignore the complexity, dynamics, and ecology of the gut microbiome.  We hypothesized 
that the structure of the microbial community was the essential variable driving 
tumorigenesis in the colon.  To test this we perturbed the gut microbiome with an 
antibiotic cocktail of metronidazole, streptomycin, and vancomycin.  This modulation of 
the gut microbiome resulted in a dramatic decrease in tumor burden in the colons of 
mice.  Importantly, treatment with this cocktail did not result in a significant decrease in 
overall bacterial load.  This strongly supported our hypothesis that the presence of a 
resident microbial community isn’t sufficient for the development of tumors; instead the 
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specific structure of the community is the driving factor.  In chapter IV, we further tested 
this hypothesis by manipulating the structure of the resident gut microbiome in mice and 
measuring subsequent effects on tumorigenesis.  To generate different community 
structures we treated mice with various combinations of the antibiotics that were used in 
chapter III (metronidazole, streptomycin, and vancomycin).  Each antibiotic treatment 
resulted in a significantly different community that had varying capacities to modulate 
tumorigenesis.  Interestingly, although antibiotic treatment groups harbored significantly 
different structures, some groups had similar levels of tumorigenesis.  When we 
examined individual bacterial populations within treatment groups with high or low tumor 
burdens, we never observed the enrichment of an individual population across all 
groups with similar levels of tumors.  Comparison of the gut microbiome dynamics 
within a low and high tumor burden treatment groups, revealed similar enrichment of the 
potentially inflammatory Enterobacteriaceae clade.  However, increased tumorigenicity 
associated with Enterobacteriaceae was only observed when there was a 
corresponding decrease in protective bacterial populations.  The observations made in 
chapter IV, suggest that various bacteria within the gut microbiome confer the same 
function and be playing redundant tumor-modulating roles.  Furthermore, these results 
support a model by which the pathogenicity of individual members of the gut 
microbiome is mediated by the community structure and ecological interactions with 
other members in the gut microbiome.  We hypothesize that inflammatory and 
carcinogenic commensal bacteria, such as Enterobacteriaceae, can only mediate a 




Potential Mechanisms of Gut Microbiome-Mediated Tumorigenesis (CRC) 
 The specific mechanisms by which dysbiosis of the gut microbiome promotes 
tumorigenesis remain largely unclear.  We hypothesized that dysbiosis of the gut 
microbiome likely leads to enrichment in tumor-promoting bacteria and loss of tumor-
repressing bacteria.  One mechanism by which certain bacterial populations drive 
tumorigenesis is through the induction of an inflammatory immune response.  An 
inflammatory environment fosters the development of cancer through the production of 
genotoxic reactive oxygen species and pro-tumor inflammatory mediators, such as 
TNF-α, IL-6, IL-1β, and IL-23.  A recent study by Kostic and colleagues reported such a 
phenomenon with the common mouth commensal, Fusobacterium nucleatum [Kostic et 
al., 2013].  They reported that F. nucleatum was enriched in tumor biopsies from CRC 
patients.  Using a mouse model, they determined that F. nucleatum increases 
tumorigenesis through the recruitment of immune cells and subsequent generation of a 
pro-inflammatory environment.  In our mouse studies we did not observe any 
Fusobacterium, but when we looked at the stool of CRC patients in chapter II, we 
observed significantly higher levels of Fusobacterium OTUs when compared to healthy 
and adenoma patients.  It is likely that the microbial community alterations we observed 
in chapter III and IV are enriched with populations that fill a similar role.   
Another potential mechanism for the development of a pro-inflammatory 
environment in the colon is through the degradation of host-secreted mucin by resident 
microbes.  Mucin is a host glycol-protein that is secreted by goblet cells in the 
gastrointestinal tract and acts as a protective liner between the host epithelium and the 
resident gut microbiome [Hollingsworth et al., 2004].  When this layer of mucin is 
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compromised, microorganisms can invade the host epithelium and cause inflammation.  
Furthermore, it is hypothesized that mucins bind and sequester cytokines, growth 
factors, and other mediators of inflammation [Hollingsworth et al., 2004].  Upon 
degradation of mucin these inflammatory factors may be released and stimulate an 
inflammatory response.  In chapter III and IV, we observed significant enrichment of 
bacterial populations belonging to the Akkermansia and Mucispirillum genera.  These 
bacteria were both enriched during the time course of tumorigenesis and antibiotic 
treated mice with increased tumor burden showed marked out growth of Mucispirillum.  
Members of the Akkermansia and Mucispirillum genera are known mucin-degrading 
bacteria.  We hypothesize that this increase in relative abundance of these bacterial 
populations may result in a thinning of the protective mucin layer.  Disruption of this 
mucin layer has been shown to enhance the ability of opportunistic pathogens to invade 
the mucosa [Ganesh et al., 2013].  We postulate that during tumorigenesis, abnormal 
levels of mucin degradation could subsequently lead to a dramatic increase in invasion 
by gut microbiota, release of mucin-associated inflammatory factors, and a subsequent 
reubust inflammatory response.  Additional studies are needed to identify the role of 
Akkermansia and Mucispirillum spp. in inflammation and tumorigenesis. 
In addition to contributing to inflammation, dysbiotic microbiomes are likely 
enriched in bacteria with a more direct role in tumor development through the 
production of toxins, virulence factors, and other tumor-promoting gene products.  A 
recent study by Arthur and colleagues demonstrated that chronic inflammation in an IL-
10 deficient mouse alters the gut microbiome, leading to an enrichment of tumor-
promoting E. coli [Arthur et al., 2012].  These strains of E. coli harbor a polyketide 
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synthase (pks) genotoxic island, which produces Colibactin, a requirement for increased 
tumor multiplicity and invasion in this model.  In each of my mouse and human studies 
we did not detect any significant changes in the genus Escherichia, but it is likely that 
other bacterial populations are playing a similar role.  Specifically, we observed a 
marked increase in Bacteroides species during tumorigenesis in chapter III.  Following 
the first signs of tumors, this population became enriched to over 10% of the 
community.  Furthermore, there was a correlation between the relative abundance of 
this OTU at the endpoint of the model and an increased tumor burden.  Members of the 
Bacteroides genus, including enterotoxigenic B. fragilis (ETBF), have been associated 
with diarrheal disease, inflammation, and CRC [Sears et al., 2008].  Specifically it is 
estimated that 5-35% of adults carry ETBF, which produces a metalloprotease toxin, B. 
fragilis toxin (BFT).  ETBF has been strongly associated with colonic tumors in multiple-
intestinal-neoplasia mice through the secretion of this toxin, which augments the host 
cell cycle [Wu et al., 2009].  We did not detect ETBF our mice, but it is possible that 
similar processes are occurring during tumorigenesis in our mice.   
We hypothesize that an equally important mechanism driving tumorigenesis in 
the colon is the loss of members of the gut microbiome that are important for 
maintaining epithelial health and immune homeostasis.  Recent evidence suggests that 
anti-inflammatory members of the gut microbiome are an important variable in the 
maintenance of gut homeostasis.  Homeostasis is necessary in order to tolerate the 
large number of potentially pro-inflammatory, TLR stimulating resident bacteria.  
Resident bacteria mediate immunotolerance in several ways, including direct inhibition 
of inflammatory pathways.  A classic example is the anti-inflammatory role of the 
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common human commensal B. thetaiotaomicron in the gut.  Studies have shown that B. 
thetaiotaomicron can antagonize NFκB mediated inflammation by targeting the active 
NFκB subunit, RelA, for transport out of the nucleus [Kelly et al., 2004].  This prevents 
downstream NFκB mediated cytokine and chemokine production.  Presumably, a loss of 
B. thetaiotaomicron, and other NFκB-modulating bacteria would lead to an increase in 
the inflammatory response to resident microbes.  Another immunomodulatory 
mechanism mediated by the gut microbiome is the production of anti-inflammatory 
metabolites, such as butyrate.  Butyrate is a type of short-chain fatty acid (SCFA), which 
are by-products of bacterial fermentation of complex carbohydrates in our diet (e.g. 
fiber).  Butyrate has been shown to reduce inflammation in the gastrointestinal tract 
through several mechanisms.  It can inhibit NFκB signaling through the inhibition of IκBα 
degredation [Segain et al., 2000] and also stimulate T-regulatory cell mediated 
homeostasis in the lamina propria.  In addition to its anti-inflammatory properties, 
butyrate also has more direct effects on tumorigenesis, including inhibition of growth 
and induction of apoptosis in cancer cells [Hague et al., 1995; Ruemmele et al., 2003].  
Therefore, the loss of butyrate-producing populations in the gut microbiome could 
increase both inflammation and tumorigenesis.  In chapter III, we observed a dramatic 
decreased in several OTUs from unclassified genera within the family 
Porphyromonadaceae.  Furthermore, in chapter IV when performing microbial 
biomarker discovery analysis we identified several bacterial populations that were 
significantly depleted in CRC.  Individuals with carcinomas showed a dramatic loss in 
OTUs associated with the genera Clostridium and Bacteroides, and the family 
Lachnospiraceae [Louis et al., 2009; Atarashi et al., 2011; Smith et al., 2013; Round et 
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al., 2010]. Each of these bacterial taxa are well known producers of SCFA in the colon 
We hypothesize that loss of these important bacterial populations in concert with an 
enrichment of pathogenic populations likely plays a synergistic role in potentiating 
tumorigenesis. 
Based on the findings presented in my thesis and the synthesis of evidence from 
the literature, I have proposed a model for the role of dysbiosis in CRC (Figure 5.1).  In 
summary, shifts in the structure of the gut microbiome lead to an imbalance between 
pro- and anti-inflammatory signals in the gut and a loss of intestinal homeostasis.  In the 
case of tumorigenesis, this leads to an increase in bacterial populations that are 
inflammatory and a loss of populations that produce anti-inflammatory signals.  These 
shifts in the microbial community initiate a strong pro-inflammatory response, which in 
turn results in further perpetuation of dysbiosis.  The synergistic effect of these two 
forces generates a self-reinforcing inflammatory cascade between the gut microbiome 
and the host.  This inflammatory environment fosters the development of cancer 
through the production of genotoxic reactive oxygen species and inflammatory 
mediators, such as TNF-α, IL-6, IL-1β, and IL-23.  A chronic inflammatory environment 
in concert with the tumor development can lead to the enrichment of bacterial 
populations that have a direct role in tumor progression through the production of toxins, 






Figure 5.1. Proposed model of gut microbiome mediated modulation of 
tumorigenesis. A. Interaction between the gut microbiome and mucosa during 
intestinal homeostasis.  There is a balance between pro and anti-inflammatory signals 
from the gut microbiome mediating immune tolerance and homeostasis.  B. The gut 
during dysbiosis and tumor development.  There is an increase in pro-inflammatory 
bacteria and a loss of protective bacteria.  This leads to increased toxin production and 
inflammation.  Inflammation creates a pro-tumor environment and further perpetuated 
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The Gut Microbiome as a Therapeutic Target for CRC 
Based on our proposed model, we postulated that the gut microbiome is a viable 
therapeutic target for CRC.  In chapter III we modulated the gut microbiome with a 
cocktail of antibiotics during the time course of tumorigenesis.  The results of this 
experiment provided a proof of principle that direct targeting of the gut microbiome can 
reduce colon tumorigenesis.  To further explore the potential of the gut microbiome as a 
therapeutic target, we explored the effect of targeting the community in a more clinically 
relevant way.  In chapter IV, mice were treated with an antibiotic cocktail 
(metronidazole, streptomycin, and vancomycin) following the first signs of dysbiosis in 
the gut microbiome.  The results of this experiment revealed that modulation of the gut 
microbiome following dysbiosis significantly minimized tumor development in mice.  This 
is an important finding because it demonstrates the concept that the gut microbiome is a 
viable therapeutic intervention in CRC.  In a clinical setting, it is unlikely that broad-
spectrum antibiotics would be recommended as a practical preventative measure for 
CRC.  Instead we suggest that manipulation of the gut microbiome be performed by 
using methods such as prebiotics, probiotics, and changes in diet.  It is known that diets 
high in fiber can lead to an increase in beneficial microbes that produce anti-cancer 
metabolites, such as butyrate.   
In order to identify specific microbes that could be targeted for enrichment or 
probiotic therapies, it is necessary to perform studies that identify protective bacterial 
populations.  Towards this goal, in chapter IV we used various antibiotic therapies to 
generate communities with differing protective and carcinogenic properties.  By focusing 
on the groups that developed the fewest tumors, we identified several potential bacterial 
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populations with potential protective properties.  These bacteria included members of 
the genera Lactobacillus, Enterococcus, and Clostridium, and members of the family 
Porphyromonadaceae.  Lactobacillus spp. have long been used as probiotics because 
of their ability to enhance epithelial barrier function, produce antimicrobial products, and 
elicit an anti-inflammatory response in the gut [Fernandez et al., 2011]. It is possible that 
Lactobacillus spp. may also provide protection in the context of CRC.  Members of the 
Clostridium genus and Porphyromonadaceae family are known producers of butyrate in 
the colon [Louis et al., 2009; Atarshi et al., 2013] and as described earlier, this likely 
provides a strong anti-tumor effect.  It still remains unclear if these populations actively 
provide protection against tumor development.  Furthermore, additional studies are 
needed to identify the mechanisms by which they confer resistance to CRC.  Once 
these questions are answered it will be important to explore their potential as probiotics 
and determine diets that enrich these populations. 
 
Future Directions 
 One of the inherent limitations of the work presented in this thesis is our inability 
to assess the gut microbiome at a functional level.  Using 16S rRNA sequences we are 
only given a broad view of bacterial populations and we can only speculate on the 
functional activity of the community.  In order understand the principal mechanisms 
behind the role of the gut microbiome in CRC; we will need to focus on the specific 
functions being performed by the community.  My hypothesis is that during 
tumorigenesis there are functional changes to the gut microbiome that lead to the 
production of pro-tumor gene products and metabolites.  Furthermore, there is a loss of 
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protective gene products and metabolites.  Two methods that can be used to test this 
hypothesis are transcriptomics and metabolomics.  Transcriptomics is a way to capture 
the mRNA from a bacterial community.  This can allow for a better understanding of 
what genes are being expressed in the gut microbiome during tumorigenesis.  
Metabolomics is a method to measure the concentration of metabolites being produced 
by bacterial communities.  I propose that by analyzing the expression profile and 
metabolite production of the gut microbiome during tumorigenesis, we will be able to 
identify important functions driving tumorigenesis.  
In the work described in this thesis we identified several bacterial populations 
that were associated with an increased or decreased tumor burden.  Outside of this 
correlation and synthesis of previous literature, we were unable to pinpoint specific 
features, gene products, or mechanisms by which these bacterial populations 
modulated tumor development or progression.  In order to begin to answer these 
questions, I propose that we perform targeted culturing of several bacterial populations 
that we identified in this thesis.  Those populations include Bacteroides spp., 
Mucispirillum spp., Porphyromonadaceae spp., Clostridium spp., and Lactobacillus spp., 
among others.  By using 16S rRNA sequences from chapter III and IV, we can perform 
plate wash PCR as described by Stevenson and colleagues [Stevenson et al., 2004].  
This will allow us to identify and target these specific populations.  I next propose that 
we perform gnotobiotic experiments with these bacterial populations.  Using the germ-
free mouse facility at the University of Michigan, we can mono-associate mice with 
these strains and determine there carcinogenicity.  Since it is difficult to determine if 
bacterial populations are protective using a germ-free model, we can also introduce 
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potentially protective isolates, like Lactobacillus, to conventional mice by repeated 
gavage.  I expect that we will be able to isolate the majority of our target bacterial 
populations and determine their tumor modulating ability.  Following these experiments, 
we can begin to perform in vitro assays to identifying the genes involved in modulating 
tumorigenesis using genetic screens and genomics.  Identification of these tumor 
modulating genes and bacteria will give us important insight into the microbial influence 
of tumor development.  Additionally, this will allow us to determine the feasibility of using 
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